



Ishita Drugs & Industries Limited

"Our basic drugs in the service of humanity worldwide"

ISHITA DRUGS AND INDUS	STR	IES LTD. 29 th ANNUAL REPORT 2021-22
		TWENTY- NINTH ANNUAL REPORT
Board of Directors	:	Mr. Jagdish Agrawal - Managing Director Mr. Govind Gupta - Director Mrs. Abha Agrawal - Director Mr. Niranjan Agrawal - Director Mr. Arvind Sapkal - Director
Chief Financial Officer	:	Mr. Sumit Agrawal
Bankers	:	Union Bank ICICI Bank Ltd. Punjab National Bank
Auditors	:	M/s. Jaymin Shah & Associates Chartered Accountants, Ahmedabad.
Secretarial Auditor	:	M/s. Meenu Maheshwari & Associates Practicing Company Secretaries Ahmedabad
Corporate Office	:	401, 3 rd EYE -II, Opp.Parimal Garden, C.G.Road, Ahmedabad - 380 006.
Registered Office & Factory	:	Survey No. 179/1, Village : Vasna-Iyava, Taluka : Sanand, District : Ahmedabad
Website	:	www.ishitadrugs.com
Investors' Complaints may be addressed to	:	Ms. Srushti Pandya Company Secretary and Compliance Officer at Corporate office. E-mail: investors@ishitadrugs.com

ANNUAL GENERAL MEETING

On Friday, 30thSeptember, 2022 at 11.30 A.M.

NOTICETOTHE SHAREHOLDERS

Notice is hereby given that the TWENTY- NINTH ANNUAL GENERAL MEETING of the Members of ISHITA DRUGS AND INDUSTRIES LIMITED (CIN: L24231GJ1992PLC017054) will be held on Friday, 30thSeptember, 2022 at 11.30 a.m. at "Manthan", Hotel Krsna Lila, Nr. Rexroth Bosch, Village Iyava, Taluka Sanand, Sanand Viramgam Highway, Gujarat 382170 to transact the following business:

ORDINARY BUSINESS:

To consider, and if thought fit, to pass, all the following resolutions as an Ordinary Resolution:

- To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2022, together with the Reports of Board of Directors and Auditors thereon.
- To appoint a Director in place of Mrs. Abha Agrawal (DIN 01589479), who retires by rotation and, being eligible, offers herself for re-appointment.
- To consider the re-appointment of M/s Jaymin shah & Associates, Chartered Accountants (FRN No. 129406W) as the Statutory Auditors of the company for a period of one year:
 - "RESOLVED THAT pursuant to the provisions of section 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 and rules framed there under, as amended from time to time, the Company hereby appoints M/s. Jaymin Shah & Associates, Chartered Accountants (FRN No. 129406W) as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting (AGM) till the conclusion of the next Annual General Meeting of the Company on such remuneration plus applicable taxes, out-of-pocket expenses, etc. as may be mutually agreed between the Board of Directors of the Company and the Auditors."

SPECIAL BUSINESS:

4. To Consider and, if thought fit, to pass with or without modification, the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provision of Section 13, 61 and other applicable provision, if any, of the Companies Act, 2013, including any statutory modification and reenactment thereof for the time being in force, and any rules framed there under, consent of the Board of Directors be and are hereby accorded to increase the Authorized Share Capital of the Company from existing ₹3,50,00,000/- (Rupees Three Crore Fifty Lakhs only) divided into 35,00,000/- (Thirty Five lakhs) equity shares of ₹10/-(Rupees Ten only) each to ₹6,00,00,000/- (Sixty lakhs) equity shares of ₹10/- (Rupees Ten Only) each."

"RESOLVED FURTHER THAT the Memorandum of Association of the Company be and is hereby altered by substituting the existing clause V thereof by following new clause V as under:

V. The Authorised Share Capital of the Company is

₹6,00,00,000/- (Rupees Six Crore Only) divided into 60,00,000/-(Sixty lakhs) equity shares of ₹ 10/- (Rupees Ten Only) each."

"RESOLVED FURTHER THAT Managing Director of the Company be and is hereby authorized to do all such acts, deeds, things and take all such necessary and expedient steps to give effect to this resolution."

 To Consider and, if thought fit, to pass with or without modifications, the following resolution as a Special Resolution:

"RESOLVED THAT pursuant to the provision of section 14 and all other applicable provisions of the Companies Act, 2013 read with the Companies (Incorporation) Rules, 2014, including any statutory modification or reenactment thereof, for the time being in force, and subject to the necessary approvals as may be required, the existing Articles of Association of the Company be and is hereby replaced with the new set of Articles of Association, and the new set of Articles of Association be and is hereby approved and adopted as the Articles of Association of the Company in place of and in substitution of the existing Articles of Association of the Company."

"RESOLVED FURTHER THAT Managing Director of the Company be and is hereby authorized to do all such acts, deeds and things and take all necessary steps to give effect to this resolution."

Notes

- a) A member entitled to attend and vote in the meeting is also entitled to appoint one or more proxies to attend and vote instead of him and not later than 48 hours before the time fixed for holding the meeting.
- b) Members are requested to advise immediately any change in their address to the Company.
- c) Corporate members intending to send their authorized representatives to attend the Meeting pursuant to section 113 of the Companies Act, 2013 are requested to send to the Company, a certified copy of the relevant Board Resolution/Authority letter, authorizing their representative(s) to attend and vote on their behalf at the Meeting.
- d) In case of joint holders attending the meeting, only such joint holder who is higher in the order of names will be entitled to vote.
- e) Member Register and Share Transfer books shall remain closed from 24.09.2022 to 30.09.2022 (both days inclusive).
- f) Members may avail of the facility of nomination in terms of section 72 of the Companies Act, 2013 by nominating any person to whom their shares in the Company shall vest on occurrence of events stated in Form SH-13. Form SH-13 is to be submitted in duplicates to Big Share Services Private Limited. (Big Share), RTA of the Company. In case of shares held in dematerialized form, the nomination has to be lodged with the respective Depository Participant.
- g) Relevant documents referred to in the accompanying notice and the Explanatory Statement thereto, are open for

- inspection at the registered office of the Company on all working days (barring Tuesday and Sunday) between 11.00 a.m. to 5.00 p.m. prior to the date of AGM.
- h) Members who have not registered their e-mail address so far are requested to register their e-mail address for receiving all communication including Annual Report, Notices, Circulars, etc. from the Company electronically.
- i) In line with the 'Green Initiative in the Corporate Governance' launched by the ministry of Corporate affairs, Electronic Copy of the Notice of Annual General Meeting of the Company inter alia indicating the process and manner of e-voting along with Attendance slip and Proxy Form are being sent to all the members whose e-mail IDs are registered with the Company/Depository Participants(s) and have given their positive consent to receive the same through electronic means. Members other than above, physical copies of the Notice of the Annual General Meeting (AGM) of the Company inter alia indicating the process and manner of e-voting along with attendance slip and Proxy Form are being sent in the permitted mode.
- j) The Securities and Exchange Board of India (SEBI) has decided that securities of listed companies can be transferred only in dematerialized w.e.f. December 05, 2018 onwards. In view of the above and to avail various benefits of dematerialization, members are advised to dematerialize shares held by them in physical form.
- k) Non Resident Indian members are requested to inform Big Share/respective DPs, immediately of:
- i. Change in their residential status on return to India for permanent settlement.
- ii. Particulars of their Bank Account maintained in India with complete name, branch, account type, account number and address of the bank with pin code number, if not furnished earlier.
- Members may also note that the notice of Annual General Meeting will also be available on the Company's website www.ishitadrugs.com
- m) A route map showing directions to reach the venue of the Annual General Meeting is given as per requirement of Secretarial Standards-2 on General Meetings.

n) Voting through electronic means:

- In compliance with provisions of Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is pleased to provide members facility to exercise their right to vote on resolutions proposed to be considered at the Annual General Meeting (AGM) by electronic means and the business may be transacted through e-Voting Services. The facility of casting the votes by the members using an electronic voting system from a place other than venue of the AGM ("remote e-voting") will be provided by National Securities Depository Limited (NSDL).
- ii. The facility for voting through ballot paper shall be made available at the AGM and the members attending the meeting who have not cast their vote by remote e-voting shall be able to exercise their right at the meeting

- through ballot paper.
- iii. The members who have cast their vote by remote evoting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again.
- iv. The e-voting facility will be available during the voting period as indicated herein below:

Electronic Voting Event Number : (EVEN) : 121341						
Commencement of e-voting End of e-voting						
Tuesday, 27 th September, 2022 at 10.00 am IST	Thursday, 29 th September, 2022 at 5.00p.m. IST					

During this period members of the Company, holding shares either in physical form or in dematerialized form, as on the cutoff date of 23rd September, 2022 may cast their vote by remote e-voting. The remote e-voting module shall be disabled by NSDL for voting thereafter. Once the vote on a resolution is cast by the member, the member shall not be allowed to change it subsequently.

v. The process and manner for remote e-voting are as under:

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

<u>Login method for Individual shareholders holding securities in demat mode is given below:</u>

I. Individual Shareholders holding securities in demat mode with NSDL

- 1. Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period.
- If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp
- Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the

icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.

II. Individual Shareholders holding securities in demat mode with CDSL

- Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or www.cdslindia.com and click on New System Myeasi.
- After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of e-Voting service provider i.e. NSDL. Click on NSDL to cast your vote.
- 3. If the user is not registered for Easi/ Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration
- 4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. **NSDL** where the e-Voting is in progress.

III.Individual Shareholders (holding securities in demat mode) login through their depository participants

You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. Upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details				
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30				
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738 or 022-23058542-43				

B) Login Method for e-Voting shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

- 1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
- Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
- 3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
 - Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
- 4. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12********* then your user ID is 12************************************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001**** and EVEN is 101456 then user ID is 101456001***

- 5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
 - c) How to retrieve your 'initial password'?
 - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the pdf file. The password to open the. pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The pdf file contains your

- 'User ID' and your 'initial password'.
- (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.
- 6. If you are unable to retrieve or have not received the " Initial password" or have forgotten your password:
 - a) Click on "Forgot User Details/Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
- 7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
- 8. Now, you will have to click on "Login" button.
- After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically on NSDL e-voting system.

How to cast your vote electronically on NSDL e-Voting system?

- After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle
- Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period now you are ready for e-Voting as the Voting page opens.
- 3. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
- Upon confirmation, the message "Vote cast successfully" will be displayed.
- 5. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
- Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

- Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to maheshwarics@yahoo.com with a copy marked to evoting@nsdl.co.in.
- 2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
- In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.:

1800 1020 990 and 1800 22 44 30 or send a request to evoting@nsdl.co.in

Process for those shareholders whose email ids are not registered with the depositories/ company for procuring user id and password and registration of e mail ids for evoting for the resolutions set out in this notice:

Shareholders may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing below mentioned documents.

- In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card).
- 2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card). If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e.Login method for e-Voting for Individual shareholders holding securities in demat mode.

Please note the following:

- i. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting as well as voting at the AGM through ballot paper.
- ii. Meenu Maheshwari, Practicing Company Secretary of Meenu Maheshwari & Associates has been appointed as the Scrutinizer for providing facility to the members of the Company to scrutinize the voting and remote e-voting process in a fair and transparent manner.
- iii. The Chairman shall, at the AGM, at the end of discussion on the resolutions on which voting is to be held, allow voting with the assistance of scrutinizer, by use of "Ballot Paper" for all those members who are present at the AGM but have not cast their votes by availing the remote evoting facility.
- iv. The Scrutinizer shall after the conclusion of voting at the Annual General Meeting, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than three days of the conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
- v. The Results declared along with the report of the Scrutinizer shall be placed on the website of the Company (www.ishitadrugs.com) and on the website of NSDL immediately after the declaration of result by the Chairman or a person authorized by him in writing. The results shall also be immediately forwarded to the BSE Limited, Mumbai.

By order of the Board of Directors For Ishita Drugs & Industries Ltd.

Sd/-

Place: Ahmedabad Jagdish Agrawal Dated: 30th May, 2022 Managing Director

29th ANNUAL REPORT 2021-22

ISHITA DRUGS AND INDUSTRIES LTD.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF COMPANIES ACT, 2013

ITEM NO. 2

Mrs. Abha Jagdishprasad Agrawal (DIN: 01589479) is Non-Executive Director of the Company. She retires by rotation, and being eligible, has offered herself for re-appointment. No remuneration is proposed to be paid to her.

Additional information on Director recommended for re-appointment as required under Regulation 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and Secretarial Standards – 2 as prescribed by the Institute of Company Secretaries of India is provided in Annexure 1 hereto.

None of the Directors, except Mrs. Abha Jagdishprasad Agrawal, and Mr. Jagdish Agrawal, Managing Director of the Company, are in any way concerned or deemed to be interested in the proposed resolution at Item No. 2 of the Notice.

The Board of Directors of your Company recommends that the Resolution under Item No. 2 be passed in the interest of the Company.

ANNEXURE 1

Name of the Director :	Mrs. Abha Agrawal
DIN:	01589479
Age & Date of Birth :	71 years, February 12, 1951
Date of first appointment on the Board :	05.02.1992
Qualifications:	M. A. (Psychology)
Directorship in other Companies :	Ishita Overseas Private Limited Anvi Lifesciences Private Limited
Membership of Committee	Member of : 1. Nomination and Remuneration Committee 2. Stakeholders Relationship Committee
No. of Board Meetings attended during the Financial Year 2021-22:	4/4 (Four)
No. of shares held in the Company:	2,35,601 (7.88%)
Relationship with other Directors / KMP	No relationship with any Directors / KMP except : Mr. Jagdish Agrawal, Managing Director (Spouse) Mr. Sumit Agrawal, CFO (Son)
Proposed Remuneration	NIL

ITEM NO.4:

The present Authorized Share Capital of the Company is ₹3,50,00,000/-(Rupees Three Crore Fifty lakhs Only) divided into 35,00,000 (Thirty Five lakhs) Equity Shares of ₹10/-(Rupees Ten) each.

In order to avoid any delay in raising fund during any unforeseen exigencies on account of breach of Authorised Capital limit, it is proposed to raise the limit by enhancing the Authorised Share Capital from ₹3,50,00,000/- (Rupees Three Crore Fifty lakhs Only) divided into 35,00,000 (Thirty Five lakhs) Equity shares of ₹10/-(Rupees Ten) each to ₹6,00,00,000/- (Rupees Six Crore Only) divided into 60,00,000 (Sixty lakhs) Equity Shares of ₹10/- (Rupees Ten) each. The Board of Directors of the Company at its Meeting held on 30th May, 2022, had accorded its approval for the same.

Consequently, Clause V of the Memorandum of Association would also require alteration so as to reflect the changed Authorised Share Capital of the Company.

Pursuant to section 61 of the Companies Act, 2013, the proposed increase in Authorised Capital and the consequential changes in Clause V of the Memorandum will require the approval of the Shareholders at a General Meeting.

None of the Directors and Key Managerial Personnel of the Company are in anyway concerned or interested in this resolution.

The consent of the Shareholders is, therefore, being sought for passing the aforesaid resolution of the notice as an Ordinary Resolution.

ITEM NO.5:

The Article of Association of the Company as presently in force was adopted when Company was incorporated under Companies Act, 1956 and further amendments were adopted from time to time under provisions of Companies Act, 1956.

The existing Articles of Association and Memorandum of Association of the Company, based on the Companies Act, 1956 are no longer in conformity with the Companies Act, 2013.

In view of substantive changes affected in corporate laws consequent to the notification of the Companies Act, 2013, it is proposed to adopt a new set of Article of Association to align the provisions contained in the Articles with the provisions of Companies Act, 2013.

As per the provisions of Section 13 and Section 14 of the Companies Act, 2013, a special resolution has to be passed by the Shareholders of the Company for adoption of revised Articles of Association and Memorandum of Association of the Company.

The Board recommends the above resolution to the shareholders for their approval as a Special Resolution.

None of the directors or Key Managerial Personnel of the Company or their relatives are concerned or interested in the said resolution.

By order of the Board of Directors For Ishita Drugs & Industries Ltd.

Sd/-

Place: Ahmedabad Dated: 30th May, 2022 Jagdish Agrawal Managing Director

DIRECTORS' REPORT

Dear Shareholders,

We have pleasure in presenting the **Twenty- Ninth Annual Report** together with the Audited Financial Statement for the year ended on 31stMarch, 2022.

FINANCIAL RESULTS

The financial performance of the Company for the financial year ended 31st March, 2022 is summarized below:

₹ in Lacs

	For the year ended 31.03.2022	For the year ended <u>31.03.2021</u>
Turnover & other incomes	1419.67	1426.26
Operating gross profit	119.73	123.15
Financial Charges	(2.46)	(3.16)
Depreciation	(12.98)	(14.61)
Profit before tax & after exceptional items	104.30	105.37
Provision for Income Tax	(25.00)	(23.00)
Provision for Deferred Tax	1.20	0.59
Net profit / loss (-)	80.50	82.96

REVIEW OF BUSINESS OPERATIONS & FINANCIAL PERFORMANCE

The Board is pleased to mention that despite the 2nd wave of COVID-19 during the year, the Company has achieved total revenue of ₹1419.67 lakhs, a marginal decrease of 0.46% over the previous year total revenue of ₹1426.26 lakhs. During the year under review, the Company earned a net profit of ₹80.50 lakhs against ₹82.96 Lakhs in the previous year, a decrease of nearly 2.97%, largely on account of higher provisioning for Income Tax.

The Board would also like to mention that the Company is totally debt free as on March 31, 2022. The Company has adequate built up reserves and liquidity for its operational and growth needs.

FUTURE OUTLOOK

During the year under review, your Company has obtained GMP certification in October 2021, which will allow us to increase exports to unregulated and semi-regulated countries.

The COVID-19 pandemic has greatly affected the economic scenario in the country and around the world. In the aftermath of the pandemic, there are worldwide issues of inflation, lower demand and recessionary trends in the economy. The API industry is further facing issues of volatility and fluctuation in prices of raw material and lower demand. This is likely to affect the performance of the company to some extent.

During the COVID-19 pandemic period, the Govt. of India had given some relaxations to the API industry and your Company

had applied for obtaining Environmental Clearances (EC) at that time. The Company is hopeful of being granted the same during the current year. On obtaining the EC and other local Consents, the Company would be in a position to add new products to its portfolio and / or manufacture additional quantities of products. This would help the Company to achieve better growth in its revenues in the long term.

SHARE CAPITAL

There was no change in share capital of the Company during the year under review. The Authorised Capital of the Company as on 31st March, 2022 is ₹3,50,00,000/- (Rupees Three Crores Fifty Lakhs Only) divided in to 35,00,000 (Thirty Five Lakhs) Equity share of ₹10/- (Rupees Ten only) each.

During the current year, Board of Directors of the Company at its Meeting held on 30th May, 2022, proposed to increase the Authorised Share Capital to ₹6,00,00,000/- (Rupees Six Crore Only) divided into 60,00,000 (Sixty Lakhs) Equity Shares of ₹10/- (Rupees Ten) each. The Board recommends the same for approval.

The Paid up Capital of the Company is ₹2,99,03,000/-(Rupees Two Crores Ninety Nine Lakhs Three Thousand Only) divided in to 29,90,300 (Twenty Nine Lakh Ninety Thousand Three Hundred) Equity share of ₹10/- (Rupees Ten Only) each.

DIVIDEND

Keeping in view the future strategic initiatives of the Company, the Board has not recommended any dividend for the year ended 31st March, 2022.

DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS

The Company has adequate and effective internal controls to provide reasonable assurance on achievement of its operational, compliance and reporting objectives. The Company has reviewed and discussed with the Management the Company's major financial risk exposures and taken steps to monitor and control such exposure.

DETAILS OF SUBSIDIARY/JOINT VENTURES/ ASSOCIATE COMPANIES

Your Company does not have any Subsidiary or Joint Venture or Associate Company.

DEPOSITS

During the year ended March 31, 2022, the Company has not accepted any public deposits and as such, no amounts on account of principal or interest on public deposits were outstanding as on the date of the Balance Sheet.

EXTRACT OF THE ANNUAL RETURN

The extract of the annual return in Form No.MGT - 9 shall form part of the Board's report and is set out as **Annexure A** to this Report.

<u>DISCLOSURES RELATING TO MANAGERIAL</u> REMUNERATION

The information required under Section 197 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of Directors / employees of your Company is set out in **Annexure B** to this report. Company does not have any employee, who was in receipt of remuneration in excess of limits specified in the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

STATUTORY AUDITORS:

Pursuant to the provisions of Section 139 and other applicable provisions, if any of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, including any amendments if any thereof, Company appoints M/s Jaymin Shah & Associates, Chartered Accountants (FRN: 129406W) as Statutory Auditors of the Company, for the period of one year i.e. from the conclusion of this (29th) AGM till the conclusion of next (30th) AGM of the Company.

The Auditors' Report on the financial statements for the financial year 2021-22 does not contain any qualification, reservation, or adverse remarks. The remarks made in the Auditors' report are self explanatory.

SECRETARIAL AUDIT

Pursuant to the provision of Section 204 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors has appointed M/s Meenu Maheshwari & Associates, Company Secretaries in Practice, to undertake the Secretarial Audit of the Company.

Secretarial Audit Report given by Ms. Meenu Maheshwari, Practicing Company Secretary [COP No. 8953] is set out as **Annexure C** and Certificate of Non disqualification of Directors as **Annexure D** to this Report. The Secretarial Audit Report does not contain any qualification, reservation or adverse remark or disclaimer.

NUMBER OF BOARD MEETINGS CONDUCTED DURING THEYEAR

During the year under review, 4 (Four) meetings of the Board of Directors were held. Details on Composition of the Board and its Committees, including the dates and terms of reference is provided in the Corporate Governance Report which forms part of this Annual Report.

MATERIAL CHANGES AND COMMITMENTS

There are no such material changes and commitments, affecting the financial position of the Company which has occurred between the end of the financial year ended March 31, 2022 and the date of report.

PARTICULARS OF EMPLOYEE

There are no employees employed by the Company throughout the financial year or for a part of the financial year who were drawing remuneration above the limits provided in section 197 (12) of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and therefore there are no details required to be given in the report.

DIRECTORS AND KEY MANAGERIAL PERSONNEL:

- (a) Mrs. Abha Agrawal (DIN: 01589479) retires by rotation, and being eligible, has offered herself for reappointment. The Board has recommended her reappointment.
- (b) Declaration by an Independent Director(s): A declaration by an Independent Directors that they meet the criteria of independence as provided in subsection (6) and (7) of Section 149 of the Companies Act, 2013 has been received and there has been no change in the circumstances affecting their status as Independent Directors of the Company.

PARTICULARS OF LOANS GUARANTEES OR INVESTMENTS UNDER SECTION 186

The company has not given any loans or guarantees covered under the provisions of section 186 of the Companies Act, 2013. The details of the investments made by company are given in the notes to the financial statements.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

The particulars of every contract or arrangements entered into by the Company with related parties referred to in subsection (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto shall be disclosed in Form No. AOC-2. However Company has not entered in any transaction attracting provision of Section 188 of Companies Act, 2013. Hence AOC-2 is not required to be attached.

DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to the requirements under Section 134(5) of the Act, with respect to Directors' responsibility Statement, it is hereby confirmed that:

- In the preparation of annual accounts, the applicable accounting standards have been followed along with proper explanation relating to the material departure,
- ii. The Directors have selected such accounting policies

and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year ended 31st March, 2022 and of the profit of the Company for the financial year ended 31st March, 2022;

- iii. The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of Companies Act, 2013, for safeguarding the assets of the Company for preventing and detecting fraud and other irregularities;
- iv. The Directors have prepared the annual accounts on a going concern basis.
- v. They have laid down internal financial controls, which are adequate and are operating effectively;
- vi. The Directors have devised proper system to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

RISK MANAGEMENT POLICY

A statement indicating development and implementation of a risk management policy for the Company including identification therein of elements of risk, if any, this in the opinion of the Board may threaten the existence of the company.

The Board of Directors has duly developed and implemented a risk management policy for the company. The Policy mandates the ways in which respective risks are expected to be mitigated and monitored.

CODE OF CONDUCT

The Board has laid down a Code of Conduct for Board Members and for Senior Management and Employees of the Company ("Code"). All the Board Members and Senior Management Personnel have affirmed compliance with these Codes. A declaration signed by the Managing Director to this effect is enclosed at the end of this Report.

The Board has also laid down a Code of Conduct for Independent Directors pursuant to section 149(8) and Schedule IV to the Companies Act, 2013 via terms and conditions for appointment of Independent Directors, which is a guide to professional conduct for Independent Directors and is uploaded on the website of the Company.

DETAILS OF ESTABLISHMENT OF VIGIL MECHANISM FOR DIRECTORS AND EMPLOYEES

The Company promotes ethical behavior in all its business activities and has put in implementation of a mechanism wherein the Employees are free to report illegal or unethical behavior, actual or suspected fraud or violation of the Company's Codes of Conduct or Corporate Governance Policies or any improper activity to the Chairman of the Audit Committee of the Company or Chairman of the Company or the Compliance Officer.

The Whistle Blower Policy has been appropriately

communicated within the Company. Under the Whistle Blower Policy, the confidentiality of those reporting violation(s) is protected and they are not subject to any discriminatory practices. No personnel have been denied access to the Audit Committee.

DISCLOSURE UNDER THE SEXUAL HARRASMENT OF WOMAN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has been employing about one woman employee. The Company has in place an Anti harassment Policy in line with the requirements of the Sexual Harassment of Woman at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaint Committee is set up to redress complaints received regularly, is monitored and directly report to the Chairman & Managing Director. There was no complaint received from employee during the financial year 2021-22 and hence no complaint is outstanding as on 31.03.2022 for redressal.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS

There are no significant/material orders passed by the Regulators or Courts or Tribunals impacting the going Concern status of your Company and its operations in future.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING AND OUTGO

The statement containing the necessary information required under Section 134(3)(m) of the Companies Act, 2013, read With Rule 8(3) of the Companies (Accounts) Rules, 2014 [Chapter IX] is annexed herewith as **Annexure E**.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management Discussion and Analysis, for the year under review, as stipulated in SEBI (LODR), 2015, is presented in a separate section forming part of this Annual Report.

CORPORATE GOVERNANCE

Provisions of Regulation 27 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015, relating to Corporate Governance are not applicable to the Company. However, with a view to increase investors' trust and transparency in its operations, the Board has decided to voluntarily adopt and follow some of the provisions of the aforesaid regulations. A separate Report on Corporate Governance forms part of this Annual Report.

ACKNOWLEDGMENT

The Directors place on record deep appreciation and gratitude for the co-operation and assistance received by the Company from the staff and employees. The Board further thanks bankers, business associates, regulatory and government authorities for their continued support to the Company.

For and on behalf of the Board

Place: Ahmedabad **Jagdish Agrawal** Dated: 30th May, 2022 Managing Director

ANNEXURE A TO THE BOARD'S REPORT EXTRACT OF ANNUAL RETURNS AS ON 31ST MARCH 2022

Form No. MGT-9

[Pursuant to Section 92(3) of the Companies Act,2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

1.	CIN	L24231GJ1992PLC017054
2.	Registration Date	5 th February 1992
3.	Name of the Company	ISHITA DRUGS & INDUSTRIES LTD
4.	Category of the Company	PUBLIC COMPANY
	Sub-Category of the Company	COMPANY HAVING SHARE CAPITAL
5.	Address of the Registered office and contact	SURVEY NO.179/1, VILLAGE VASNA-IYAVA, TAL SANAND,
	details	DIST AHMEDABAD. Contact : ishitadrugs@gmail.com
6.	Whether listed company	Yes
7.	Name, Address and Contact details of Registrar	Bigshare Services Private Limited, A-802, Samudra Complex,
	and Transfer Agent, if any	Near Girish Cold Drinks, Off C.G. Road, Navrangpura,
		Ahmedbad - 380009
		Contact : bssahd@bigshareonline.com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

The entire business activities contributing 10% or more of the total turnover of the company shall be stated:-

Sr.No.	Name and Description of main products/ services	NIC Code of the Product/ service	% to total turnover of the company		
1	Manufacture of Bulk Drugs, Fine Chemicals and Intermediates	2100	100%		

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

The Company does not have any holding, subsidiary or associate company.

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Share Holding

Category of Shareholders		of Shares held at the nning of the year			No. of Shares held at the end of the year			% Change during The year	
	Demat	Physical	Total	%of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoter									
1) Indian									
a) Individual/ HUF	1004155		1004155	33.58	1047219		1047219	35.02	1.44
b) Central Govt									
c) State Govt(s)									
d) Bodies Corp	427300		427300	14.29	427300		427300	14.29	0.00
e) Banks / FI									
f) Any Other									
Sub-total(A)(1):-	1431455		1431455	47.87	1474519		1474519	49.31	1.44
2) Foreign									
g) NRIs-Individuals									
h) Other-Individuals									
i) Bodies Corp.									
j) Banks / FI									
k) Any Other									
Sub-total(A)(2):-									

29th ANNUAL REPORT 2021-22

B. Public Shareholding									
1. Institutions									
a) Mutual Funds									
b) Banks / FI									<u>-</u>
c) Central Govt									
d) State Govt(s)									
e) V. C. Funds									
f) Ins. Companies									
g) FIIs									
h) Foreign Venture									
Capital Funds									
i) Others (specify)									
Sub-total(B)(1)									
2. Non Institutions									
a) Bodies Corp.									
(i) Indian	86052	3100	89152	2.98	60711	3100	63811	2.13	(0.85)
(ii) Overseas									
b) Individuals									
(i) Individual	565115	441765	1006880	33.67	574987	436765	1011752	33.83	0.16
shareholders									
holding nominal									
share capital upto									
₹ 2 lakh									
(ii) Individual	353040	0	353040	11.81	303968	0	303968	10.17	(1.64)
shareholders									
holding nominal									
share capital in									
excess of									
Rs 2 lakh									
c) Others - NRIs									
(i) Clearing Members	87	0	87	0.00	447	0	447	0.01	0.01
(ii) NRI	83280	0	83280	2.79	27718	0	27718	0.93	(1.86)
(iii) NBFC Registered	11500	0	11500	0.38	11500	0	11500	0.38	0.00
with RBI		-				_			
(iv) Trusts	100	0	100	0.00	100	0	100	0.00	0.00
(v) HUF	14806	0	14806	0.50	96485	0	96485	3.23	2.73
Sub-total(B)(2)	1113980	444865	1558845	52.13	1075916	439865	1515781	50.69	(1.44)
Total Public	1113980	444865	1558845	52.13	1075916	439865	1515781	50.69	(1.44)
Shareholding	1110300		1000040	JZ. 10	1070910	70000	1010701	50.09	(1.77)
(B)=(B)(1)+ (B)(2)									
C. Shares held by									
Custodian for GDRs									
& ADRs									
Grand Total									
	0545405	444065	2000202	100.00	0550405	420065	2000200	100.00	0.00
(A+B+C)	2545435	444865	2990300	100.00	2550435	439865	2990300	100.00	0.00

^{*} Previous year figures have been regrouped and reclassified to be in conformity with the current year figures.

ii. Shareholding of Promoters

Sr. No	Shareholder's Name	Shareholding at the beginning of the year			Sharehol the year			
		No. of Shares	% of total Shares of the company	%of Shares Pledged to total shares	No. of Shares	Shares of	% of Shares Pledged to total shares	% change in share holding during the year
1.	AGRAWAL JAGDISHPRASAD G	85000	2.84	NIL	85000	2.84	NIL	0.00
2.	ABHA AGRAWAL	192537	6.44	NIL	235601	7.88	NIL	1.44
3.	JAGDISH AGRAWAL	205259	6.86	NIL	175259	5.86	NIL	(1.00)
4.	ISHITA AGRAWAL	25140	0.84	NIL	25140	0.84	NIL	0.00
5.	SUMIT AGRAWAL	231969	7.76	NIL	231969	7.76	NIL	0.00
6.	DIVYA SUMIT AGRAWAL	104150	3.48	NIL	104150	3.48	NIL	0.00
7.	UMANG FINANCIALSERVICES LTD.	297300	9.94	NIL	297300	9.94	NIL	0.00
8.	ISHITA OVERSEAS PVT.LTD.	130000	4.35	NIL	130000	4.35	NIL	0.00
9.	SUMIT AGRAWAL (HUF)	60000	2.01	NIL	60000	2.01	NIL	0.00
10.	VIRENDRA AGRAWAL	100	0.00	NIL	100	0.00	NIL	0.00
11.	VARLIKA SUMIT AGRAWAL	40000	1.34	NIL	40000	1.34	NIL	0.00
12.	KRISHN SUMIT AGRAWAL	60000	2.01	NIL	90000	3.01	NIL	1.00
	Total	1431455	47.87	NIL	1474519	49.31	NIL	1.44

iii. Change in Promoters' Share holding

Sr. no	Name of shareholders	Shareholding at the beginning of the year		Decrease	Increase		ative Shareholding e end of the year
		No. of % of total shares of the company				No. of shares	% of total shares of the company
1.	ABHA AGRAWAL	192537	6.44	0	43064	235601	7.88
2.	JAGDISH AGRAWAL	205259	6.86	30000	0	175259	5.86
3.	KRISHN SUMIT AGRAWAL	60000	2.01	0	30000	90000	3.01

iv. Shareholding Pattern of top ten Shareholders as on 31.03.22:

(Other than Directors, Promoters, IEPF and Holders of GDRs and ADRs):

Sr. no	Name of shareholders		eholding at the ning of the year	Cumulative Shareholding at the end of the year		
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company	
1.	PATEL BHUPESH VAHALABHAI	60142	2.01	115000	3.85	
2.	MOHAN DEEP CHANDIRAMANI HUF	NIL	NIL	82753	2.77	
3.	SANGEETHA S	50000	1.67	50000	1.67	
4.	FOREVER MERCHANTS PVT. LTD.	71490	2.39	47554	1.59	
5.	NIMMI CHANDIRAMANI	NIL	NIL	31733	1.06	
6.	VINOD DAHYALAL KOTHARI	29786	1.00	29786	1.00	
7.	ANILA DAHYALAL KOTHARI	28941	0.97	28941	0.97	
8.	SHWETA VINOD KOTHARI	26156	0.87	26156	0.87	
9.	VINODCHANDRA MULJIBHAI SHAH	22352	0.75	22352	0.75	
10.	PRATIBHA P SHAH	19784	0.66	19784	0.66	
	TOTAL	308651	10.32	454059	15.19	

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding /accrued but not due for payment

	Secured Loans	Unsecured	Deposits	Total Indebtedness
	excluding deposits ₹	Loans ₹	₹	maebleaness
Indebtedness at the beginning of the financial year				
i) Principal Amount	4,19,486			4,19,486
ii) Interest due but not paid				
iii) Interest accrued but not due				
Total(i+ii+iii)	4,19,486			4,19,486
Change in Indebtedness during the financial year				
- Addition				
- Reduction	4,19,486			4,19,486
Net Change	4,19,486			4,19,486
Indebtedness at the end of the financial year				
i) Principal Amount	00			00
ii) Interest due but not paid	00			00
iii) Interest accrued but not due	00			00
Total (i+ii+iii)	00			00

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director

Sr. No.	Particulars of Remuneration	Mr. Jagdish Agrawal	Total Amount (₹)
1.	Gross salary	42,30,000	42,30,000
2.	Stock Option	0	0
3.	Sweat Equity	0	0
4.	Commission	0	0
5.	Others, please specify	0	0
6.	Total (A)	42,30,000	42,30,000
	Ceiling as per the Act*		84,00,000

^{*} Remuneration to Managing Director is within the limits prescribed under Schedule V to the Companies Act, 2013

B. Remuneration to other Directors:

No remuneration including sitting fees is being paid to any other Director.

C. Remuneration to Key Managerial Personnel Other Than MD

Sr. no.	Particulars of Remuneration	Key Manageri		
		CFO	CS	Total ₹
1.	Gross salary	31,80,000	2,40,000	34,20,000
2.	Stock Option	0	0	0
3.	Sweat Equity	0	0	0
4.	Commission	0	0	0
5.	Others,please specify	0	0	0
6.	Total	31,80,000	2,40,000	34,20,000

VII. PENALTIES/ PUNISHMENT /COMPOUNDING OF OFFENCES:

No penalties/punishment/compounding of offences were levied under the Companies Act, 2013.

ANNEXURE B TO THE BOARD'S REPORT

Information required under section 197 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rule, 2014

A. Ratio of Remuneration of each Director to the median remuneration of all the employees of your Company for the financial year 2021-22 is as follows:

Name of	Total	Ratio of remuneration
Director	Remuneration of Director to	
	(₹)	median remuneration
Mr. Jagdish Agrawal	42.30.000/-	15.46

Notes: No remuneration is being paid to any other director. The median remuneration for all employees of the company has been calculated only for employees working with the company as on March 31, 2022.

B. Details of percentage increase in the remuneration of Director and CFO in the financial year 2021-22:

Name	Designation	Remuneration in ₹		Increase
		(PM)(Average)		
		2021-22	2020-21	(%)
Jagdish Agrawal	M. D.	3,52,500	2,80,000	26%
Sumit Agrawal	CFO	2,65,000	2,65,000	0.00

C. Percentage increase in the median remuneration of all employees in the FY 2021-22

It is not practical to ascertain the above as the type and number of employees at different levels has changed between FY 2020-21 and 2021-22.

D. Number of permanent employees on the rolls of the Company as on 31.03.22: 16 (Sixteen)

E. Explanation on the relationship between average increase in remuneration and Company performance:

There was an increase of 6.75% in remuneration of all employees in the financial year 2021-22 as compared to the financial year 2020-21. Despite the uncertainty amid the COVID-19 pandemic and the marginal decrease in revenues / profits, the increase was essential to retain employees. Remuneration of only those employees was considered who were with the Company in 2020-21 and 2021-22.

Particulars	Growth (%)
Total Revenues	(0.46)
Operating Profit	(2.78)
Profit After Tax	(2.97)

Your company offers competitive compensation to its employees. Also, the company has to offer salaries as per the prevailing industry rates, irrespective of the performance, to retain the employees. This ensures a healthy work environment and job satisfaction for the employees. Hence, there would be a positive co-relation in the increase in remuneration of the employees and the performance of the Company. However, a perfect co-relation will not be visible given the dependency of performance of the Company on other external factors.

F. Comparison of the remuneration of the Key Managerial Personnel against the performance of Your Company:

There was an increase of 26% in the remuneration of the Key Managerial Personnel during the FY 2021-22 while the net profits of the Company slightly decreased by 2.97% in the year 2021-22 compared to 2020-21.

G. Details of Share price and market capitalization

	As on 31 st	As on 31 st	Increase /
	March 2022	March 2021	(Decrease) (%)
Closing Market Price	41.35	30.00	37.83
on BSE			
Price Earnings Ratio	15.36	10.81	42.10
Market Capitalization	1236.49	897.09	37.83
(₹. lakh)			

Details of month wise highs and lows of the price of the shares of the company on the BSE and the volumes traded are given in the Report on Corporate Governance, forming a part of this Annual Report.

H. Comparison of average increase in salary of employees other than the key managerial personnel and the percentage increase in the key managerial remunerations:

There was an increase of 6.75% in the remuneration of all employees, excluding Key Managerial Personnel, during the year under review. There was an increase of 26% in the remuneration of Key Managerial Personnel in the financial year 2021-22 as compared to the financial year 2020-21. (Remuneration of only those employees was considered who were with the company in 2020-21 & 2021-22).

I. Key Parameters of the variable Component of remuneration paid to the director

The remuneration payable to the Director for the year 2021-22 does not include any variable component.

J. There are no employees of the Company who receive remuneration in excess of the highest paid Director of the Company.

K. Affirmation

Pursuant to Rule 5(1) (xii) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, it is affirmed that the remuneration paid to the Directors, Key Managerial Personnel and senior management is as per the Remuneration Policy of your Company.

L. Statement containing the particulars of employees in accordance with Rule 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rule, 2014

The company has no such employees.

ANNEXURE C TO THE BOARD'S REPORT SECRETARIAL AUDIT REPORT Form No.MR-3

For the financial year ended 31/03/2022

[Pursuant to section 204 (1) of the Companies Act, 2013 and rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To, The Members, ISHITA DRUGS AND INDUSTRIES LIMITED CIN No. L24231GJ1992PLC017054

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. ISHITA DRUGS AND INDUSTRIES LIMITED (hereinafter called the 'Company'). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, I hereby report that in my opinion, the Company

has, during the audit period covering the financial year ended 31st March, 2022, generally complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended 31st March, 2022, according to the provisions of:

- (i) The Companies Act, 2013("the Act") and the rules made there under as applicable;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- (iv) Foreign Exchange Management Act,1999 (FEMA) and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (Not applicable to the Company during the Audit Report)
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India ((Listing Obligations And Disclosure Requirements) Regulations, 2015;
 - (b) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (c) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
- (vi) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009; (Not applicable as there was no reportable event during the financial year under review)
- (vii) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999; (Not applicable as there was no reportable event during the financial year under review)
- (d) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; (Not applicable to the Company during the Audit Report)
- (e) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; (Not applicable to the Company during the Audit Report)
- (viii) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; (Not applicable as there was no reportable event during the financial year under review)
- (ix) The Securities and Exchange Board of India (Buy back of Securities) Regulations, 1998; (Not applicable as there was no reportable event during the financial year under review)
- (x) Circulars/Guidelines issued thereunder;
- (xi) I have relied on the representation made by the Company and its officers for systems and mechanism formed by the Company for compliances under other applicable Acts, Laws and Regulations to the Company. Management has identified and confirmed the following laws as being specifically applicable to the Company;
- Pharmacy Act, 1948;
- Drugs & Cosmetics Act, 1940,;
- Narcotic Drugs and psychotropic Substances Act, 1985;
- Indian Boilers Act, 1923;
- Factories Act, 1948;
- The Insecticide Act, 1968;
- Environment Protection Act, 1986 and other environmental laws
- Hazardous Wastes (Management and Handling) Rules, 1989 and
- Amendment Rule, 2003
- Maternity Benefits Act, 1961
- Sale of Goods Act, 1930
- The Payment of Gratuity Act, 1972
- The Payment of Wages Act, 1936
- Equal Remuneration Act, 1976
- The Industrial Disputes Act, 1947
- The Child Labour (Regulation & Abolition) Act, 1970

I have also examined compliance with the applicable clauses of the following:

- Secretarial Standards 1 and 2 issued by the Institute of Company Secretaries of India (applicable for the period ending 31st March, 2022);
- (ii) (ii) Listing Agreements entered into by the Company with BSE (Stock Code: 524400) (BOMABAY STOCK EXCHANGE) Limited and ASE (Stock Code: 26940) (Ahmedabad Stock Exchange) and/or Securities Exchange Board Of India (Listing Obligations And Disclosure Requirement) Regulations, 2015

During the period under review the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

I further report that -

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines; and

 As informed, the Company has responded appropriately to notices received from various statutory / regulatory authorities including initiating actions for corrective measures, wherever found necessary.

I further report that during the audit period there were no instances of;

- (i) Public/Rights/Preferential issue of shares/Debentures/Sweat Equity, etc.
- (ii) Redemption/Buy-back of securities.
- (iii) Major decision taken by the members in pursuance to Section 180 of the Companies Act, 2013,
- $\hbox{(iv) Merger/Amalgamation/Reconstruction, etc.}\\$
- (v) Foreign Technical Collaboration.

For Meenu Maheshwari & Associates

Sd/-Proprietor (Meenu Maheshwari) Company Secretaries Firm Regn No.: S2015GJ305400 ICSI UDIN : F007087D000435724 FCS No. 7087 C.P. No. 8953

Date: 30-05-2022 Place: Ahmedabad

Note:- This Report is to be read with my letter of above date which is annexed as Annexure A and it forms an integral part of this report.

ANNEXURE A OF SECRETARIAL AUDIT REPORT

To, The Members, ISHITA DRUGS AND INDUSTRIES LIMITED CIN No. L24231GJ1992PLC017054

Secretarial Audit Report of even date is to be read along with this letter.

1) Management Responsibility:

(1) It is the responsibility of the management of the company to Maintain secretarial record, devise proper system to ensure compliance with the provisions of all applicable laws and regulation and to ensure that the system are adequate and operate effectively.

2) Auditors Responsibility:

- (2) I am responsible to express an opinion on this secretarial record, standards and procedure followed by the company with respect to secretarial compliances.
- (3) I believe that audit evidence and information obtained from the company's management is adequate and appropriate for us to provide a basis for our opinion.
- (4) Wherever required, I have obtained the management representation about the compliance of laws, rules and regulation and happening of events etc.
- (5) I have not verified the correctness and appropriateness of financial records and books of accounts of the Company, and The verification was done based on the records and documents provided, on test basis to ensure that correct facts are reflected in secretarial records. I believe that the processes and practices followed by me provide a reasonable basis for my opinion.
- (6) The compliance of the provision of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedures on test basis.

3) Disclaimer:

Date: 30.05.2022

Place: Ahmedabad

The Secretarial Audit report is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the company.

I further report that I could not physically verify few documents/registers/returns due to Lockdown situation in relation to outbreak of Pandemic Covid-19 and I have relied up on the soft copies/information shared with me.

For Meenu Maheshwari & Associates

Sd/-Proprietor (Meenu Maheshwari) Company Secretaries Firm Regn No.: S2015GJ305400 ICSI UDIN : F007087D000435724 FCS No. 7087 C.P. No. 8953

ANNEXURE D TO THE BOARD'S REPORT CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

[Pursuant to Regulations 34(3) and Schedule V Para C Clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To,
The Members of
ISHITA DRUGS AND INDUSTRIES LIMITED
SURVEY NO 179/1, VASNA-IYAVA,
TALUKA, SANAND, AHMEDABAD GJ-INDIA

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of ISHITA DRUGS AND INDUSTRIES LIMITED having CIN L24231GJ1992PLC017054 and having registered office at SURVEY NO 179/1, VASNA-IYAVA, TALUKA SANAND AHMEDABAD GJ-IN and (hereinafter referred to as 'the Company'), produced before me/us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2022 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Meenu Maheshwari & Associates

Sd/-Proprietor (Meenu Maheshwari) Company Secretaries Firm Regn No.: S2015GJ305400 ICSI UDIN: F007087D000435724 FCS No. 7087 C.P. No. 8953

Date: 30.05.2022

Place: Ahmedabad

29th ANNUAL REPORT 2021-22

ANNEXURE E TO THE BOARD'S REPORT

CONSERVATION OF ENERGY

The Company has been persistently striving to achieve improved efficiency in energy consumption by consistently running the plant at very high steam efficiency, close monitoring of energy consuming equipments, optimizing the use of steam centers minimizing losses and better housekeeping. The Company continues to make strenuous efforts to conserve and optimize the consumption of energy through improved operational methods.

FORM - A

Form for disclosure of particulars with respect to the conservation of energy.

POWER AND FUEL CONSUMPTION

	2021-22	2020-21
1) Electricity (a) Purchased units KWH (GEB) Total amount ₹ Average Rate per Unit ₹	80026 771837 9.64	73390 704355 9.60
(b) Own Generation through D.G. Amount of Diesel Units of Diesel consumed (Ltrs)		
2) Other Fuels ₹	1501345	1742012

CONSUMPTION PER UNIT OF PRODUCTION

It is impractical to apportion the consumption and cost of utilities to each product in view of multiplicity of products.

RESEARCH AND DEVELOPMENT

The Company through its R&D efforts has made significant progress in various activities like Process Development, Analytical Methods, Development and Chemical Synthesis.

FORM-B

Form of disclosure of particulars with respect to the technology absorption.

(A) Research and Development (R&D)

Specific areas in which R&D is carried out by the Company.

- Process development for newer bulk drugs and process improvement for existing product
- Development of new analytical methods for quality control and quality assurance during production.

2. Benefits derived as a result

- Successful Commercialization of the process developed by R&D department significant savings due to in house process development.
- Better margins due to improvement in yields.
- Improved quality of products due to adaptation of better methods of analysis by quality assurance.

3. Future plan of action

Research and Development efforts will be continued

in process development. The Company is considering technical tie-ups with Indian and Foreign research institutes for new molecules in the chemical and biotechnology spheres.

Expenditure on R & D:

	2021-22	2020-21
(a) Capital		
(b) Recurring	₹ 169966	₹ 156899
Total (a+b)	₹ 169966	₹ 156899
(c) Total R&D expenditure as a	0.12%	0.11%
percentage of total turnover		

(B) Technology Absorption, Adaptation and Innovation

- 1. Efforts, in brief, made towards technology absorption, adaptation and innovation:
 - Our R&D laboratory has carried out detailed experiments for the Process development of drug intermediates.
- 2. Benefits derived as a result of the above efforts, e.g., development, import substitution, etc.:-
 - Commercial Production of the specialty chemical product (Drug Intermediate) may be taken up in near future
- In case of imported technology (imported during the last five years reckoned from the beginning of the financial year) Nil

(C) Foreign exchange earnings and outgo (2021-22)

a) Foreign Exchange Earning - ₹ 1,18,88,657

(PY ₹ 1,73,21,339)

b) Foreign Exchange Outgo - ₹ 2,25,39,530

(PY ₹ 2,33,19,439)

For and on behalf of the Board

Sd/-

Place: Ahmedabad Dated: 30th May, 2022 **Jagdish Agrawal** Managing Director

REPORT ON CORPORATE GOVERNANCE & GENERAL SHAREHOLDER INFORMATION A. REPORT ON CORPORATE GOVERNANCE

I. Company's philosophy on Corporate Governance:

Your company has always adapted the highest ethical standards in business and good Corporate Governance practices so that positive aspects of a "family-run" business are combined with the assurance that investors' interests would be recognized and addressed.

The salient features of the company's philosophy on corporate governance are:

- Compliance with all Statutory laws as also other rules / requirements regarding directors / related person remuneration, disclosures, etc.
- 2. Clear separation of company owned resources and personal accounts
- Reliance on structures and processes that are recognized as good and moral corporate practices rather on "family" persons, making it a truly professionally managed Company.
- 4. Full transparency in functioning and accountability of management to the Board
- Internal controls and Risk management under supervision of Independent Directors
 - With transparent and honest administrative practices, the management of your company believes it can further increase investors trust and work responsibly to maximize all shareholders value.

II. GOVERNANCE STRUCTURE AND ROLE AND RESPONSIBILITIES

Company's governance structure comprises of Board of Directors, Committees of the Board and the Management.

Board of Directors:

Composition:

As on date, the Board of Directors of your Company comprises Five (5) Directors of which Three (3) are Non-Executive Independent Directors, one (1) is a Non-Executive Promoter Director and one is Managing Director of the Company. The composition of the Board is in conformity with Regulation 27 and suitable applicable provisions of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (hereinafter referred to as "SEBI (LODR) Regulations, 2015"). The details of the Directors being appointed / re-appointed on retirement by rotation at the ensuing Annual General Meeting, as required pursuant to Regulation 27 and suitable applicable provisions of SEBI (LODR) guidelines, are mentioned in the Notice to the Annual General Meeting, forming part of the Report.

Number of Board Meetings:

During the year under review, 4 (Four) meetings of the Board of Directors were held as on 31st March, 2022. The time gap, between the first meeting of financial year 2021-22 (30.06.21) and the last meeting of financial year 2020-21 (04.02.21), exceeded the maximum stipulated time gap of 120 days between two meetings. However, vide Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/556 dated 29th April, 2021, SEBI had given a special exemption from observing the maximum stipulated time gap during this period, on account of COVID-19. For other meetings, the time gap between two (2) meetings did not exceed four (4) months.

Date(s) on which meeting(s) were held:

Board Meeting was held on 30/06/2021,13/08/2021, 02/11/2021 and 14/02/2022.

The Board meets at least once in a quarter to review the quarterly financial results and operations of the Company. In addition to the above, the Board also meets as and when necessary to address specific issues relating to the business.

Committees of the Board:

Currently, there are Three (3) Committees of the Board, namely: Audit Committee, Nomination & Remuneration Committee and Stakeholder Relationship committee. The Board decides the terms of reference for these Committees. The minutes / report of the meetings of the Committees are placed before the Board for information and action thereon, if any. The details as to the composition, terms of reference, number of meetings etc., of these Committees are provided hereunder:

AUDIT COMMITTEE:

The Committee comprises three independent directors and one non-independent director and is chaired by an Independent Director.

The constitution of Audit Committee meets with the requirements of Corporate Governance guidelines as well as the provisions of Section 177 of the Companies Act, 2013 and Regulation 18 and suitable applicable provisions of SEBI (LODR) guidelines. Terms of reference of appointment of Audit Committee are as under.

The Committee's terms of reference includes Powers of the Audit Committee:

- It shall have authority to investigate into any matter in relation to the items specified in Section 177 of the Companies Act, 2013 or referred to it by the Board and for this purpose, shall have full access to information contained in the records of the Company and external professional advice, if necessary.
- To investigate any activity within its terms of reference.
- > To seek information from any employee.
- To obtain outside legal or other professional advice.
- > To secure attendance of outsiders with relevant expertise, if it considers necessary

Responsibilities of the Audit Committee:

- Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible.
- Recommending the appointment and removal of external auditor, fixation of audit fees and also approval for payment for any other services.
- Reviewing with management the annual financial statements before submission to the Board.
- Reviewing the findings if any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.
- Reviewing the adequacy of internal audit function and discussing with the internal auditors on the significant findings and further course adopted.

Audit Committee met four times during the F.Y. 2021-22 on 30/06/2021, 13/08/2021, 02/11/2021 and 14/02/2022. All the Meetings were also attended by the Auditors of the Company.

NOMINATION AND REMUNERATION COMMITTEE: Composition and terms of reference:

In Compliance of section 178 of Companies Act, 2013 the Nomination and Remuneration Committees comprise of four directors out of which three directors are Independent directors and one is Non-executive director in the Committee, and an Independent Director acts as the Chairman of the Committee.

The Committee's terms of reference includes:

 Reviewing and recommending to the Board – the salary, commission, other benefits, service agreements and

- 29th ANNUAL REPORT 2021-22
- employment conditions of the Whole-time and the Managing Director and
- Approve the selection, appointment and remuneration of relatives of Directors for holding an office of profit pursuant to Section 188 of the Companies Act, 2013.

Date(s) on which the meeting(s) were held

During the financial year ended 31st March, 2022, Four (4) Committee Meetings were held on 30/06/2021, 13/08/2021, 02/11/2021 and 14/02/2022

Details of remuneration paid to the Directors of the Company are as follows:

Managing Director:

The present remuneration of the Managing Director (as per terms of re-appointment w.e.f from October 1, 2021) includes a salary of Rs. 4,25,000/- per month and other perquisites, as approved by the Nomination and Remuneration Committee and the Shareholders at the AGM held on 30th September, 2021. For the financial year 2021-22, the remuneration payable to Mr. Jagdish Agrawal is reviewed by the Nomination and Remuneration Committee.

Non-Executive Directors:

The Non-Executive Directors on the Board of your company are very senior and experienced professionals, and play a crucial role in defining the overall growth strategy of the Company. They also play a pivotal role in safeguarding the interests of the investors at large by playing an appropriate control role. Their active involvement in the Company's business processes and their independent views ensure a very high level of governance in the Company.

The Non-Executive directors are providing honorary services and have not been paid any salary, sitting fees, performance based incentives or any stock options during the financial year 2021-22.

Relatives of the Directors

The Chief Financial Officer of the Company, Mr. Sumit J. Agrawal, is related to the Managing Director, Mr. Jagdish Agrawal and another promoter director, Mrs. Abha Agrawal. As such, his appointment and remuneration is approved by the Remuneration Committee. The present remuneration of the CFO is ₹ 2,65,000/- per month, and other perquisites, as approved by the Remuneration Committee. For the financial year 2021-22, the remuneration payable to Mr. Sumit Agrawal is reviewed by the Remuneration Committee.

STAKEHOLDER RELATIONSHIP COMMITTEE:

Composition and terms of reference:

As per sub-section (5) section 178 of Companies Act, 2013 the Share transfers committee has been merged in to Stakeholder Relationship Committee.

The Stakeholder Relationship Committee duly Constituted and comprise of Three (3) directors out of which two directors are Independent directors and one is Non-executive director in the Committee and the committee is chaired by Non Executive Director to specifically look into the redressal of shareholders queries and complaints.

The terms of reference of the Committee include, inter-alia, the following:

To specifically look into queries and complaints received from the shareholders of the Company,

- To oversee the performance of the Registrar and Transfer Agent of the Company, and
- To recommend measures for overall improvement in the quality of services to the investors.
- > To effect transfer of shares;
- > To effect transmission or deletion of shares;
- To issue duplicate share certificates, issue of certificate on receipt of requests for rematerialization, consolidation or split of share certificates;
- To approve the register of members as on the record date(s) and/ or book closure dates for receiving dividends and other corporate benefits:

INVESTOR COMPLAINTS	
1 Pending at the beginning of the year	NIL
2 Received during the year	NIL
3 Disposed of during the year	NIL
4 Remaining unresolved at the end of the year	NIL

Date(s) on which the meeting(s) were held

During the financial year 2021-22, the Committee met four times on 30/06/2021, 13/08/2021, 02/11/2021 and 14/02/2022. There were no pending complaints at the end of the financial year 2021-22.

III. General Body Meetings:

The venue and the time of the last three Annual General Meetings of the Company are as follows:

Year	Location	Meeting Date	Time	No. of Special Resolution set Out at the AGM
2020-21	"The Cascade" Pam Inn Regency Hotel, Nr. HP Petrol Pump, Village Vasana Iyava, Tal. Sanand, Sanand Viramgam Highway, Gujarat 382170	30/09/21	11.30 AM	1
2019-20	Survey No 179/1, Vasna-Iyava, Taluka Sanand	30/09/20	3.00 PM	0
2018-19	Taluka Sanand Ahmedabad Gujarat 382210 In	30/09/19	3.00 PM	0

There was no Extra Ordinary General Meeting (EGM) held during the year ended March 31, 2022.

All special resolutions set out in the notices for the Annual General Meetings were passed by the shareholders at the respective meetings with requisite majority.

IV. Disclosures:

a) Disclosures on materially significant related party transactions:

Your Company has not entered into any transaction of a material nature except transactions with related parties which are furnished under Notes to the Financial Statements as stipulated under Indian Accounting Standard 24 (AS-24), with the Promoters, Directors or the Management, their subsidiaries or relatives etc. All transactions were carried out on an arms-length basis and were not prejudicial to the interest of the Company.

b) Disclosures on non-compliances by the Company:

Your Company has complied with all the requirements of the Stock Exchange(s) and the Securities Exchange Board of India on matters related to Capital Markets or any other matter, as may be applicable from time to time. There were no penalties imposed or strictures passed against the Company by the statutory authorities in this regard.

c) Disclosure of Accounting Treatment:

Your Company follows Accounting Standards prescribed by the Companies Accounting Standard Rules, 2006 and relevant provisions of the Companies Act, 2013. In preparation of financial statements, the Company has not adopted a treatment different from that prescribed in the Accounting Standards.

d) Details of compliance with mandatory and non-mandatory requirements of Regulation 27 and suitable applicable provisions of SEBI (LODR) Regulations 2015 of the Listing Agreement:

As already mentioned in the Director's Report, the provisions of the Regulation 27 and suitable applicable provisions of SEBI (LODR) Regulations, 2015, do not apply to the Company. However, the company has voluntarily chosen to adopt and follow certain provisions of the Regulation 27 and suitable applicable provisions of SEBI (LODR) Regulations 2015. The company complies with all the mandatory requirements of the SEBI (LODR) Regulations 2015 with regard to corporate governance.

e) Vigil mechanism

The company has established vigil mechanism for directors, employees and other stakeholders to report concerns about unethical behavior, actual or suspected fraud or violation of the company's code of conduct or the ethical policy.

The company has provided opportunities to encourage employees to become whistle blowers. It has also ensured a mechanism within the same framework to protect them from any kind of harm. It is hereby affirmed that no personnel has been denies access to the audit committee.

1. AGM for the F.Y 2021-22	30/09/2022 at 11.3	30/09/2022 at 11.30 a.m. at "Manthan", Hotel Krsna Lila, Nr. Rexroth Bosch, Village Iyava,						
		Taluka Sanand, Sanand Viramgam Highway, Gujarat 382170						
2. Date of Book closure		9/2022 (both days inclusive						
3. Listing on Stock Exchanges		524400) & ASE (Scrip C	,					
4. Share Registrar			mudra Complex, Nr. Girish Colo	Drinks, off C.G. Road,				
-	Navrangpura, Ahm	edabad - 380009						
5. Share Transfer System	The shares of the	company are compulsorily t	raded in dematerialized form. S	Shares received in physical				
	form are transferre	d within a period of 30 days	from the date of lodgement su	bject to documents being vali				
	and complete in all	respects						
6. De-materlisation of Shares	As on 31/03/22, ap	prox. 85.29% shares of the	company were held in de-mat	erialized form				
7. Market Data : High, Low	Month	High (₹)	Low (₹)	Volume (Nos)				
during each month in last	Apr-21	35.00	27.15	18775				
financial year 2021-22	May-21	36.00	28.55	28998				
	Jun-21	35.15	27.25	44932				
	Jul-21	54.00	28.60	223955				
	Aug-21	44.90	36.10	45827				
	Sep-21	42.95	36.00	28282				
	Oct-21	54.45	40.00	39336				
	Nov-21	50.90	34.00	17792				
	Dec-21	48.75	35.40	96094				
	Jan-22	52.90	41.55	77522				
	Feb-22	53.40	36.10	46148				
	Mar-22	45.05	36.40	28933				

GREEN INITIATIVE IN CORPORATE GOVERNANCE:

Pursuant to Circular No. 17/2011 dated 21stApril, 2011 and Circular No. 18/2011 dated 29thApril, 2011, Ministry of Corporate Affairs (MCA) has launched "Green Initiative in Corporate Governance" whereby the companies are allowed to send notices, documents and other communication to the shareholders in electronic mode. In view of the above circulars issued by MCA, your Company proposes to send documents like the Notice convening the general meetings, Financial statements, Directors' Report, Auditors' Report, etc to the email address provided by you to your Depository Participant (DP). Your Company encourages its shareholders to support the "Green Initiative" by registering their email addresses with their respective depositories/ Company's Registrar and Transfer Agent and intimate changes in the email address from time to time.

MANAGEMENT DISCUSSION & ANALYSIS REPORT

GENERAL INFORMATION ABOUT THE COMPANY

The company is engaged in the business of manufacturing of various APIs (Active Pharma Ingredients) and drug intermediates. It has built up a reputation as a manufacturer of "high quality" products and is known for its ethical dealings in business. The company supplies its products to leading pharmaceutical companies of India. The products are also being exported to various countries across the world.

NATURE OF THE INDUSTRY

The Indian API industry has been facing a challenging business environment for last few years. With opening up of the Indian markets and signing of the WTO arrangement, the imported APIs and Intermediates became available at a very competitive price. This impacted the indigenous API and Intermediates manufacturers, who could not compete with the imported pricing. The Indian API industry has also been affected by stringent pollution control norms. Presently, almost 60-70% of total APIs consumed in India are imported. Over a period of time, the manufacturing capabilities & capacities for APIs in India has gone down. However, due to the COVID-19 pandemic, the present Govt. has recognized the importance of reducing dependence on China for APIs and has affirmed its commitment to encourage domestic API industry by introducing special measures for its development.

OPPORTUNITY AND THREAT:

The biggest threat for the API industry is from imports. Further, due to the ongoing uncertainity in the aftermath of the COVID-19 pandemic, the industry faces other operational risks due to manpower shortage. logistics problems, raw material availability, subdued demand etc. Other threats include requirement of resources for continuous up gradation of the facility as per the GMP standards. This is especially more important for small scale industries like your Company.

The Company has taken advantage of relaxations granted by the Govt. for Environmental Clearances during the COVID-19 pandemic and had applied for an Environmental Clearance (EC) to the appropriate authority. As and when it is approved, the Company can take further steps to increase the product portfolio of the Company, which will help improve capacity utilization and add to the top line. The company has also obtained GMP Certification in October 2021, which will help increase exports to the unregulated and semi-regulated markets. Your company, with it's built up reserves and debt free status, is in a good position to take advantage of any other such measures declared by the Govt.

FUTURE OUTLOOK:

The management's opinion on the future outlook for the Company is given under the Directors' Report forming part of the Annual Report of the company.

INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:

The Company has adequate and effective internal controls to provide reasonable assurance on achievement of its operational, compliance and reporting objectives.

The Company has deployed controls through its policies and procedures. It helps the Management to accomplish its objectives by bringing a systematic and disciplined approach to improve the effectiveness of risk management towards good corporate governance. The Directors handle most of the day to day functions. The Directors are regularly looking after all the key areas of the

DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:

The management's view on the business operations and financial performance of the company, including export performance and earnings, is given under the Directors' Report forming part of the Annual Report of the company.

MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONT, INCLUDING NUMBER OF PEOPLE EMPLOYED:

The Company's operations are managed by technically and educationally qualified staff at all levels, who in turn are guided and supervised by the Directors of the Company. During the year under review, the company has increased the number of employees to better look after the various operations and to prepare for a better growth in the future.

CAUTIONARY STATEMENT:

Statement in the Management Discussion and Analysis, describing the Company's objective, projections and estimates are forward looking statements and progressive within the meaning of applicable security Laws and Regulations. Actual results may vary from those expressed or implied, depending upon economic conditions, Government Policies and other incidental factors.

DECLARATION OF COMPLIANCE WITH THE CODE OF CONDUCT

I hereby confirm that the company has obtained from all the members of the Board and employees at senior management level, affirmation that they have complied with the code of conduct for Board of Directors and senior management level employees.

For and on behalf of the Board

Sd/-Jagdish Agrawal Place: Ahmedabad Managing Director Dated: 30th May, 2022

CERTIFICATE PURSUANT TO REGULATION 17(8) OF THE LISTING REGULATIONS

Mr. Jagdish Agrawal, Managing Director and Mr. Sumit Agrawal, CFO of the company shall certify that, to the best of our knowledge and belief:

- 1. They have reviewed the balance sheet and profit and loss account and all its schedules and notes on accounts, as well as the cash flow statements and the Directors' Report;
- These statements do not contain any materially untrue statement or omit any material fact nor do they contain statements that might be misleading;
- These statements together present a true and fair view of the company, and are in compliance with the existing accounting standards and / or applicable laws / regulations;
- They are responsible for establishing and maintaining internal controls and have evaluated the effectiveness of internal control systems of the company; and they have also disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, and what they have done or propose to do to rectify
- They have also disclosed to the auditors as well as the Audit Committee, instances of significant fraud, if any, that involves management or employees having a significant role in the company's internal control systems; and
- They have indicated to the auditors, the Audit Committee and in the notes on accounts, whether or not there were significant changes in internal control and / or of accounting policies during the year.

For and on behalf of the Board

Sd/-

Sd/-

Place: Ahmedabad Dated: 30th May, 2022

Jagdish Agrawal Managing Director **Sumit Agrawal CFO**

INDEPENDENT AUDITOR'S REPORT TOTHE MEMBERS OF ISHITA DRUGS AND INDUSTRIES LTD.

Report on the Financial Statements

We have audited the accompanying financial statements of **ISHITA DRUGS AND INDUSTRIES LTD.** ("The Company"), which comprise the Balance Sheet as at **31/03/2022**, the Statement of Profit and Loss, **the cash flow statement** for the year ended, and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error, In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at **31/03/2022**, and its **Profit and it's cash flows** for the year ended on that date.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditors' Report) Order,2016("the Order") issued by the Central Government of India in terms of sub section (11) of section 143 of the Companies Act, 2013. We give in the Annexure A statements on the matters specified in paragraphs 3 and 4 of the order, to the extent applicable.

As required by Section 143 (3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss, and the cash flow statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31/03/2022 taken on record by the Board of Directors, none of the directors is disqualified as 31/03/2022 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
- The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.
- There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

Date: 30th May, 2022 Place: Ahmedabad FOR Jaymin Shah & Associates Chartered Accountants

Reg No. : 129406W

Sd/-CA Mayank Sancheti Partner M.No. : 170863

UDIN : 22170863AJWBOK4326

ANNEXURE - A Reports under The Companies (Auditor's Report) Order, 2016 (CARO 2016) for the year ended 31st March 2022

To,

The Members of ISHITA DRUGS AND INDUSTRIES LTD.

We report that: -

SI. No.	Comment Required on	Auditor's Opinion on Following Matter	Auditor's Remark
(i)	Fixed Assets	a) Whether the company is maintaining proper records showing full particulars, including quantitative details and situation of fixed assets?	The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.
		b) Whether these fixed assets have been physically verified by the management at reasonable intervals; whether any material discrepancies were noticed on such verification and if so, whether the same have been properly dealt with in the books of accounts?	Fixed assets have been physically verified by the management at reasonable intervals; No material discrepancies were noticed on such verification.
		c) Whether the title deeds of immovable properties are held in the name of the company? If not, provide the details thereof.	Yes, held in the name of Company.
(ii)	Inventory	Whether physical verification of inventory has been conducted at reasonable intervals by the management and whether any material discrepancies were noticed and if so, whether they have been properly dealt with in the books of account?	Physical verification of inventory has been conducted at reasonable intervals by the management.
(iii)	Loans Secured or Unsecured Granted	Whether the company has granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the register maintained under section 189 of The Companies Act, 2013? if so,	As informed, the company, company has not granted any loans, secured or unsecured to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013.
		a) Whether the terms and conditions of the grant of such loans are not prejudicial to the company's interest?	As informed, the company, company has not granted any loans, secured or unsecured to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013.
		b) Whether the schedule of repayment of principal and payment of interest has been stipulated and whether the repayments or receipts are regular?	As informed, the company, company has not granted any loans, secured or unsecured to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013.
		c) If the amount is overdue, state the total amount overdue for more than ninety days, and whether reasonable steps have been taken by the company for recovery of the principal and interest?	As informed, the company, company has not granted any loans, secured or unsecured to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013.
(iv)	Loan to director and investment by the company	In respect of loans, investments, guarantees, and security whether provisions of section 185 and 186 of the Companies Act, 2013 have been complied with. If not, provide the details thereof.	While doing transaction for loans, investments, guarantees, and security provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.
(v)	Public Deposits	In case, the company has accepted deposits, whether the directives issued by the Reserve Bank of India and the provisions of sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 and the rules framed thereunder, where applicable, have been complied with? If not, the nature of such contraventions be stated; If an order has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other tribunal whether the same has been complied with or not?	
(vi)	Cost Accounting Records	Whether maintenance of cost records has been specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 and whether such accounts and records have been so made and maintained?	To the best of our knowledge and as explained, the Central Government has not prescribed maintenance of cost records under sub-section (1) of section 148 of the Companies Act, 2013 for the products of the company.

ISHITA DRUGS AND INDUSTRIES LTD. 29th ANNUAL REPORT 2021-22 Statutory Compliance a) Whether the company is regular in depositing The company is regular in depositing the undisputed (vii) undisputed statutory dues including provident fund, statutory dues including provident fund, employees` employees' state insurance, income tax, sales-tax, state insurance, income tax, sales, tax wealth tax, service tax, duty of customs, duty of excise, value service tax, custom duty, excise duty. Cess and other added tax, cess and any other statutory dues to the statutory dues applicable to the Company with the appropriate authorities and if not, the extent of the appropriate authorities. No undisputed amounts arrears of outstanding statutory dues as on the last day payable in respect of the aforesaid statutory dues of the financial year concerned for a period of more were outstanding as at the last day of the financial than six months from the date they became payable, year for a period of more than six months from the shall be indicated? date they became payable. b) Where dues of income tax or sales tax or service tax There is no dispute with the revenue authorities or duty of customs or duty of excise or value added tax regarding any duty or tax payable. have not been deposited on account of any dispute, then the amounts involved and the forum where dispute is pending shall be mentioned. (A mere representation to the concerned Department shall not be treated as a dispute) (viii) Loan from Banks/ Whether the company has defaulted in repayment of The company has not defaulted in repayment of dues loans or borrowing to a financial institution, bank, to financial institution, bank or debenture holders. Financial Institution government or dues to debenture holders? If yes, the period and the amount of default to be reported (in case of defaults to banks, financial institutions, and government, lender wise details to be provided) Application of Money Whether moneys raised by way of initial public offer or The company has not raised any money by way of (ix) further public offer (including debt instruments) and initial public offer or further public offer {including debt Received from Equity term loans were applied for the purposes for which instruments) and term loans. Hence this clause is not those are raised. If not, the details together with delays or Loan applicable. or default and subsequent rectification? if any, as may be applicable, be reported. Whether any fraud by the company or any fraud on the (x) Fraud Reporting Based on our audit procedures and the information Company by its officers or employees has been noticed and explanation made available to us no such fraud noticed or reported during the year. or reported during the year? If yes, the nature and the amount involved is to be indicated; (xi) Managerial whether managerial remuneration has been paid or Managerial remuneration has been paid or provided provided in accordance with the requisite approvals in accordance with the requisite approvals mandated Remuneration mandated by the provisions of section 197 read with by the provisions of section 197 read with Schedule V Schedule V to the Companies Act? If not, state the to the Companies Act. amount involved and steps taken by the company for securing refund of the same. Whether the Nidhi Company has complied with the Net Nidhi Company -As per information and records available with us The (xii) Owned Funds to Deposits in the ratio of 1:20 to meet company is not Nidhi Company. Compliance with out the liability and whether the Nidhi Company is maintaining ten per cent unencumbered term deposits Deposits as specified in the Nidhi Rules, 2014 to meet out the liability? (xiii) Related Party Whether all transactions with the related parties are in Yes, All transactions with the related parties are in compliance with section 177 and 188 of Companies compliance with section 177 and 188 of Companies Transactions Act, 2013 where applicable and the details have been Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc., as required disclosed in the Financial Statements etc., as required by the applicable accounting standards. by the applicable accounting standards? (xiv) Issue of Share Whether the company has made any preferential No Preferential allotment or Private Placement

Date: 30th May, 2022 Place: Ahmedabad

(xv)

(xvi)

Capital and use of

Amount Raised

Transaction with

Registration from RBI

Director

FOR Jaymin Shah & Associates

of shares done during the Financial Year Under

The company has not entered into any non-cash

Act, 2013 have been complied with.

transactions with directors or persons connected with

him and the provisions of section 192 of Companies

The company is not required to be registered under

section 45-IA of the Reserve Bank of India Act.

Consideration.

Chartered Accountants Reg No.: 129406W

CA Mayank Sancheti Partner

M.No. : 170863 UDIN : 22170863AJWBOK4326

allotment or private placement of shares or fully or

partly convertible debentures during the year under

Whether the company has entered into any non-cash

transactions with directors or persons connected with

him and if so, whether the provisions of section 192 of

Whether the company is required to be registered under

section 45-IA of the Reserve Bank of India Act, 1934

and if so, whether the registration has been obtained?

Companies Act, 2013 have been complied with?

review and if so, as to whether the requirement of section 42 of the Companies Act, 2013 have been complied with and the amount raised have been used for the purposes for which the funds were raised. If not, provide the details in respect of the amount involved

and nature of non-compliance?

"Annexure B"

To the Independent Auditor's Report of even date on the Standalone Financial Statements of ISHITA DRUGS AND INDUSTRIES LTD. Company Ltd.

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **ISHITA DRUGS AND INDUSTRIES LTD.**Company Limited ("The Company") as of March 31, 2022 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence amount the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and operating effectiveness of internal control based on the assessed risk. The procedures selected depend upon on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit

opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issues by the Institute of Chartered Accountants of India.

Date: 30th May, 2022 Place: Ahmedabad FOR Jaymin Shah & Associates Chartered Accountants Reg No.: 129406W

> Sd/-CA Mayank Sancheti Partner M.No. : 170863

UDIN: 22170863AJWBOK4326

BALANCE SHEET AS AT 31ST MARCH, 2022

(Amount in ₹)

S.N	PARTICULARS	Note	Τ	As at	As at
		No		31/03/2022	31/03/2021
Ι	ASSETS				
1	NON-CURRENT ASSETS				
	(a) PROPERTY, PLANT AND EQUIPMENT	A	8845583		9957703
	(b) FINANCIAL ASSETS	_			
	(i) INVESTMENTS	В	2714554		2258747
	(ii) LOANS	С	507200		507200
	TOTAL(1)			12067337	12723650
2	CURRENT ASSETS				
_	(a) INVENTORIES	D	9737062		6544262
	(b) FINANCIAL ASSESTS		0.0.00_		0011202
	(i) INVESTMENTS	E	37932104		28849952
	(ii) TRADE RECEIVABLES	_	5419515		15237771
	(iii) CASH AND CASH EQUIVALENTS	F	19867592		17532207
	(iv) OTHER BALANCES WITH BANK	G .	26951779		7851063
	(v) LOANS	H	329940		3646950
	(c) OTHER CURRENT ASSETS	''	234413		263430
	TOTAL(2)	']	100472405	79925634
	TOTAL ASSETS(1+2)			112539742	92649284
II	EQUITY AND LIABILITIES				
1	EQUITY				
	(a) EQUITY SHARE CAPITAL	J	29903000		29903000
	(b) OTHER EQUITY	K	56053478		48003810
	TOTAL (1)			85956478	77906810
2	NON-CURRENT LIABILITIES (a) FINANCIAL LIABILITIES				0
	(b) DEFERRED TAX LIABILITIES (NET)		290903		410889
	TOTAL(2)		230300	290903	410889
		1			
3	CURRENT LIABILITIES				
3	CURRENT LIABILITIES (a) FINANCIAL LIABILITIES				
3			20388218		9824103
3	(a) FINANCIAL LIABILITIES	L	20388218		9824103 419486
3	(a) FINANCIAL LIABILITIES (i)TRADE PAYABLES	L	1		
3	(a) FINANCIAL LIABILITIES (i)TRADE PAYABLES (ii)OTHER CURRENT FINANCIAL LIABILITIES	L M	0		419486
3	(a) FINANCIAL LIABILITIES (i)TRADE PAYABLES (ii)OTHER CURRENT FINANCIAL LIABILITIES (b) OTHER CURRENT LIABILITIES	_	0 1850310		419486 1090679
3	(a) FINANCIAL LIABILITIES (i)TRADE PAYABLES (ii)OTHER CURRENT FINANCIAL LIABILITIES (b) OTHER CURRENT LIABILITIES (c) PROVISIONS	_	0 1850310 891143	26292360	419486 1090679 766386

As per our attached report of even date.

Sd/-For Jaymin Shah & Associates Chartered Accountants Sd/-**Jagdish Agrawal** Managing Director Sd/-**Govind Gupta** Director

Ahmedabad Dated : 30th May, 2022 Sd/-**Mrs.Abha Agrawal** Director Sd/-**Sumit Agrawal** CFO

29th ANNUAL REPORT 2021-22

STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED ON 31ST MARCH, 2022

(Amount in ₹)

S.N	PARTICULARS	Note No		Year 2021-22	Year 2020-21
	INCOME				
1	REVENUE FROM OPERATIONS		140904934		139490072
II	OTHER INCOME	PL-1	1061611		3135679
Ш	TOTAL INCOME (I+II)			141966545	142625751
IV	EXPENSES:				
	(a) COST OF MATERIAL CONSUMED	PL-2	96920720		95639664
	(b) PURCHASE OF STOCK IN TRADE	PL-3	5095000		6318250
	(c) CHANGES IN INVENTORIES OF FINISHED GOODS,	PL-4	(296668)		912989
	WORK-IN-PROGRESS AND STOCK-IN-TRADE				
	(d) EMPLOYEE BENEFIT EXPENSES	PL-5	11808222		10974339
	(e) FINANCIAL CHARGES	PL-6	245894		316304
	(f) DEPRECIATION		1297537		1461401
	(g) MANUFACTURING AND OTHER EXP.	PL-7	16466158		16465416
	TOTAL EXPENSES			131536863	132088364
٧	PROFIT FOR BEFORE TAX (III-IV)			10429682	10537387
VI	TAX EXPENSE				
	(a) CURRENT TAX			2500000	2300000
	(b) DEFERRED TAX			(119986)	(58840)
VII	PROFIT / (LOSS) FOR THE YEAR			8049668	8296227
VIII	OTHER COMPREHENSIVE INCOME			0	0
IX	TOTAL COMPREHENSIVE INCOME FOR THE YEAR			8049668	8296227
Х	EARNING PER EQUITY SHARE (FACE VALUE₹ 10				
	EACH)				
	(a) BASIC			2.69	2.77
	(b) DILUTED			2.69	2.77
Notes or	n Accounts & Significant Accounting Policies	N			

As per our attached report of even date.

Sd/-For Jaymin Shah & Associates Chartered Accountants Sd/-**Jagdish Agrawal** Managing Director Sd/-**Govind Gupta** Director

Ahmedabad Dated : 30th May, 2022 Sd/-**Mrs.Abha Agrawal** Director Sd/-**Sumit Agrawal** CFO

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2022

(Amount in ₹)

			(Alliount in V
		For the Year 2021-22	For the Year 2020-21
A Cash flo	ow from operating activities :		
Profit bef	ore tax	10429682	10537387
Add :	Depreciation	1297537	1461401
	Interest & Other financial charges	245894	316304
Less :	Interest received	682265	403122
	Dividend received	3802	1118
	Income from Investments	375544	2731439
Operating pro	ofit before change in working capital	10911503	9179414
Add :	Trade Debtors	9818256	(2127959)
	Decrease / (Increase) in Inventory	(3192800)	(734948)
	Decrease /(Increase) in Loans and advances	1085077	(2183362)
Less:	Provision for Taxation	2500000	2300000
	Increase / (Decrease) Short term provisions	(884388)	(188043)
	Trade creditors, Current liabilities & Provisions	(13756824)	8769414
Net cash ger	nerated from operating activities (A)	30763248	(6748225)
B Cash inflo	ow from investing activities:		
Add :	Investment sold / (purchased)	(9537959)	21825874
	Dividend received	3802	1118
	Income from Investments	375544	2731439
Less :	Investment in fixed assets	185417	49153
Net cash gen	nerated from investing activities (B)	(9344031)	24509278
C Cash flow	v from financial activities :		
Add :	Interest received	682265	403122
Add :	Borrowing	(419486)	(2460667)
_ess :	Interest & Other financial charges	245894	316304
Net cash ger	nerated from financial activities (C)	16884	(2373849)
Net Increase	e/(decrease) in Cash & Cash Equivalents (A+B+C)	21436101	15387203
Opening bala	ance of Cash and cash equivalents & Other Bank Balances	25383270	9996067
	nce of Cash and cash equivalents & Other Bank Balances	46819371	25383270
•	e/(decrease) in Cash & Cash Equivalents & Other Bank Balances	21436101	15387203
Note : Figure	s in bracket indicate negative value		

Correctly extracted from Audited accounts of the Company

Sd/- Sd/- Sd/- Sd/- Sd/
Mrs.Abha Agrawal
Director Managing Director Director CFO

Ahmedabad

Dated: 30th May, 2022 **Auditors' Certificate**

We have verified the above cash flow statements of Ishita Drugs And Industries Limited. It has been compiled from and is based on the balance sheet as at 31st March 2022 and the related statement of profit and loss for the year ended on that date. The above cash flow statement has been prepared under the indirect method as set out in the Accounting Standard (IndAS -7) - Statement of Cash Flow.

For Jaymin Shah & Associates

Place : Ahmedabad Dated : 30th May, 2022

Chartered Accountants

29th ANNUAL REPORT 2021-22

ISHITA DRUGS AND INDUSTRIES LTD.

NOTES:

A PROPERTY, PLANT & EQUIPMENT

		Gross BI	ock			Deprec	iation		Net E	lock
Particulars	As at 01/04/21 ₹	Addition ₹	Deduction ₹	As at 31/03/22 ₹	As at 01/04/21 ₹	Addition ₹	Deduction ₹	As at 31/03/22 ₹	As at 31/03/22 ₹	As at 31/03/21 ₹
Factory Land	904811			904811					904811	904811
Plant and Machinery	24658940	49000		24707940	20858956	419539		21278495	3429445	3799984
Laboratory Equipment	2134622	49576		2184198	1679972	87679		1767651	416547	454650
Cylinders	14441			14441	14441			14441		
Effluent Treatment Plant	1608641			1608641	1528209			1528209	80432	80432
Factory Building	5905137			5905137	4585431	169542		4754973	1150164	1319706
Office Building	1264568			1264568	551969	20947		572917	691652	712599
Furniture and Fixtures	2125295			2125295	1781607	128139		1909746	215549	343688
Office Equipment	1105318			1105318	875195	94248		969443	135875	230124
Computers	923028	117540		1040568	840419	54178		894597	145971	82609
Vehicles	6877394	60640	1826785	5111249	4848293	323264	1735446	3436111	1675138	2029101
Total	47522195	276756	1826785	45972166	37564491	1297537	1735446	37126582	8845584	9957703
Previous Year	47473042	49153		47522195	36103091	1461401		37564491	9957703	11369951

(Amount in ₹)

Notes		As at 31-Mar-22	As at 31-Mar-21
В	NON CURRENT INVESTMENT		
	(a) Unquoted		
	500 Equity Shares of Textile Traders Co-operative	12500	12500
	Bank Ltd.each of ₹. 25 fully paid up		
	70000 Shares of Umang Financial Services Ltd. each	700000	700000
	of ₹ 10/- fully paid up		
	3000 Shares of Anvi Lifesciences Pvt Ltd. each	600000	600000
	of ₹100/- fully paid up		
	Aggregate value of Unquoted Investment- At cost		
	₹1312500 (PY ₹.1312500)		
	(b) Quoted		
	204 Shares of Jet Airways (India) Ltd. each	224400	224400
	of ₹ 10/- fully paid up [Market value ₹ 16361 (PY ₹ 19064)]		
	28 Shares of BSE Ltd. each	22568	22568
	of ₹ 2/- fully paid up [Market value ₹ 26432 (PY ₹ 15991)]		
	80 Shares of Avenue Supermart Ltd. each	23920	23920
	of ₹ 10/- fully paid up [Market value ₹ 319956 (PY ₹ 228324)]		
	642 Shares of SBI Cards & Payment Services Ltd. each	484710	484710
	each of ₹ 10/- fully paid up [Market value ₹ 546791 (PY ₹ 596643)]		
	352 Shares of Burger King India Limited each	21120	21120
	of ₹ 10/- fully paid up [Market value ₹ 35446 (PY ₹ 45443)]		
	112 Shares of Mrs. Bectors Food Specialities Ltd. each	32256	32256
	of ₹ 10/- fully paid up [Market value ₹ 31394 (PY ₹ 37643)]		
	34 Shares of Indigo Paints Ltd. each	50660	50660
	of ₹ 10/- fully paid up [Market value ₹ 54352 (PY ₹ 81235)]		
	30 Shares of MTAR Technologies Ltd. each	17250	17250
	of ₹ 10/- fully paid up [Market value ₹ 52449 (PY ₹ 30717)]		
	63 Shares of Nazara Technologies Ltd. each	69363	69363
	of ₹ 4/- fully paid up [Market value ₹ 103185 (PY ₹ 92292)]		

ISHI	TA DRUGS AND INDUSTRIES LTD.		29 th ANNUAL RE	EPORT 2021-22
				(Amount in ₹)
Notes			As at 31-Mar-22	As at 31-Mar-21
	41 Shares of TATVA Chintan Pharma Chem Ltd. each of ₹ 10/- fully paid up [Market value ₹ 94616 (PY N.A,)]		44403	0
	250 shares of Glenmark Life Science Ltd. each of ₹ 2/- fully paid up [Market value ₹ 114750(PY N.A,)]		180000	0
	16 shares of Rolex Rings Ltd. each		14400	0
	of ₹ 10/- fully paid up [Market value ₹ 20054 (PY N.A,)] 924 Shares of Devyani International Ltd each		83160	0
	of ₹ 1/- fully paid up [Market value ₹ 161977 (PY N.A,)] 83 shares of Krsnaa Diagnostics Ltd. each		79182	0
	of ₹ 5/- fully paid up [Market value ₹ 40301 (PY N.A,)] 148 Shares of Paras Defence and Space Technologies Ltd. eac	ch	25900	0
	of ₹ 10/- fully paid up [Market value ₹ 92589 (PY N.A,)] 146 shares of Latent View Analytics Ltd. each of ₹ 1/- fully paid up [Market value ₹ 61692(PY N.A,)]		28762	0
		Total	2714554	2258747
С	NON CURRENT LOANS			
	Security Deposits (Unsecured Considered Good Unless Otherwise stated)		507200	507200
		Total	507200	507200
D	INVENTORIES			
	As taken, valued and certified by the M.D.			
	Raw material (at cost)		7679235	3416147
	Raw Material in transit (at cost)		0	1435250
	Work in Process (at cost)		1916271	1619603
	Packing, Fuel Etc. (at cost)		141556	73262
		Total	9737062	6544262
E	CURRENT INVESTMENTS			
	Investments in units of Mutual Fund		37932104	28849952
_	OACH A CACH FOUNTAL FUTO	Total	37932104	28849952
F	CASH & CASH EQUIVALENTS Cash on hand Banks Balance		1253107	15634
	In Current Accounts		10663930	524588
	In EEFC Accounts		7950555	16991986
		Total	19867592	17532207
G	OTHER BALANCES WITH BANK			
	In Fixed Deposit Accounts	-	26951779	7851063
Н	CURRENT LOANS (Unsecured - Considered good)	Total	26951779	7851063
	Advances recoverable in cash or kind or for value to be received		329940	3646950
		Total	329940	3646950
1	OTHER CURRENT ASSETS			
	Prepaid Expenses		234413	263430
J	EQUITY SHARE CAPITAL	Total	234413	263430
	(1) Authorised : 35,00,000 Equity Shares of ₹ 10/- each(2) Issued, Subscribed and paid up :		35000000	35000000
	29,90,300 Equity Shares of ₹ 10/- each fully paid up		29903000	29903000
	-,, =quily =sies of C. of essertionly paid ap	Total	29903000	29903000

Notes	ISHI1	TA DRUGS AND INDUSTRIES LTD.		29 th ANNUAL RE	PORT 2021-22
Notes					(Amount in ₹)
(1) Capital Reserve State cash Subsidy 1500000 1500000 1500000 1500000 1500000 1500000 1500000 1500000 1500000 1500000 1500000 1500000 1500000 1500000 15000000 15000000 15000000 15000000 15000000 15000000 150000000 150000000 150000000 1500000000 1500000000 1500000000 150000000000	Notes			l	
State cash Subsidy 1500000 1500000 1500000 1500000 1500000 1500000 1500000 15000000 15000000 15000000 15000000 15000000 15000000 15000000 15000000 150000000000	K				
(2) General Reserve As per Last Balance sheet Add: Transfer surplus in statement of Profit & Loss A/c (3) Shares Forfeited (3) Shares Forfeited (3) Shares Forfeited (4) Shapes Forfeited (5) Shapes Forfeited (5) Shapes Forfeited (6) Shapes F				1500000	1500000
Add : Transfer surplus in statement of Profit & Loss A/c				1300000	1300000
3 Shares Forfeited		As per Last Balance sheet		46339310	38043083
164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 164500 1		Add: Transfer surplus in statement of Profit & Loss A/c			
Consumption of Packing Material Consumption of Packing Material Consumption of Goods Traded Consumption of Goods Traded Inventory Adjustments (a) Opening Stock Manufacturing Goods Work in process (b) Closing Stock Manufacturing Goods Work in process (c) Contribution for Pockident Fixed Contribu		(3) Shares Forfeited			
1 1 1 1 1 1 1 1 1 1		(o) onares i onered			
1 1 1 1 1 1 1 1 1 1					
PROVISIONS	L				410496
M PROVISIONS (1) Provisions For Employee Benefits & Others 891143 766386 PL-1 OTHER INCOME Interest Income 3802 1118 Interest Income Interest Income Interest Income Interest Income Interest Income Interest Income Investments 3802 1118 PL-2 COST OF MATERIALS CONSUMED: Consumption of Raw Material 96567020 95063914 Consumption of Packing Material 96567020 9503914 Consumption of Opacking Material 353699 575750 Total 96920720 95639664 PL-3 PURCHASES OF TRADED GOODS Consumption of Goods Traded Total 5095000 6318250 PL-4 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade Inventory Adjustments (a) Opening Stock Manufacturing Goods Work in process 1619603 2532592 (b) Closing Stock Manufacturing Goods Work in process 1619603 2532592 (b) Closing Stock Manufacturing Goods Work in process 1619603 2532592 PL-5 EMPLOYEE BENEFITS EXPENSE 1818271 1619603 Salary & wages & Bonus 6949327 6755768 Gratuity 6949327 6755768		(1) Current Maturities of Long Term Debts (Venicle Loan)	Total		
PL-1 OTHER INCOME Dividend Income Interest Income 682265 4031122 1118 1161611 335674 2731439 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 3135679 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 1061611 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631 106631	M	PROVISIONS	Total		110100
PL-1 OTHER INCOME Dividend Income 1802 1118 Interest Income 682265 403122 1178 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1		(1) Provisions For Employee Benefits & Others			
Dividend Income 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118			Total	891143	766386
Dividend Income 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118	DI _1	OTHER INCOME			
Interest Income Income from Investments Total Total 1061611 3135679 PL-2 COST OF MATERIALS CONSUMED: Consumption of Raw Material 96567020 95063914 353699 575750 75750 96920720 95639664 PL-3 PURCHASES OF TRADED GOODS Consumption of Goods Traded Total 5095000 6318250 PL-4 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade Inventory Adjustments (a) Opening Stock Manufacturing Goods 1619603 2532592 (b) Closing Stock Manufacturing Goods 1619603 2532592 (b) Closing Stock Manufacturing Goods 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1				3802	1118
Income from Investments					
PL-2 Cost Of Material					
Consumption of Raw Material 96567020 95063914 353699 575750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750 75750			Total	1061611	3135679
PL-3 PURCHASES OF TRADED GOODS Total S095000 6318250	PL-2	COST OF MATERIALS CONSUMED:			
PL-3 PURCHASES OF TRADED GOODS Consumption of Goods Traded Total 5095000 6318250 PL-4 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade Inventory Adjustments (a) Opening Stock Manufacturing Goods Consumption of Provident Fund Consumption of Contribution for Provident Fund Consumption of Goods Consumption of		Consumption of Raw Material		96567020	95063914
PL-3 PURCHASES OF TRADED GOODS Consumption of Goods Traded Total 5095000 6318250		Consumption of Packing Material		353699	575750
Consumption of Goods Traded Total			Total	96920720	95639664
Consumption of Goods Traded Total	PL-3	PURCHASES OF TRADED GOODS			
PL-4 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	0	· ·		5095000	6318250
PL-4 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade Inventory Adjustments (a) Opening Stock <			Total	5095000	
Net Inventory Adjustments (a-b) Total	PL-4	Changes in inventories of finished goods,			
(a) Opening Stock Manufacturing Goods Work in process 1619603 2532592 (b) Closing Stock Manufacturing Goods Work in process 1916271 1619603 Net Inventory Adjustments (a-b) Total (296668) 912989 PL-5 EMPLOYEE BENEFITS EXPENSE Salary & wages & Bonus Gratuity 6949327 6755768 Gratuity 69808 37858 Staff Welfare Exp. 415978 730115 Director's Remuneration 4230000 3360000 Contribution for Provident Fund Contribution for ESIC 104784 72520		· · · · · · · · · · · · · · · · · · ·			
Manufacturing Goods		Inventory Adjustments			
Work in process 1619603 2532592					
(b) Closing Stock Manufacturing Goods Work in process Net Inventory Adjustments (a-b) Total Total Total				4040000	
(b) Closing Stock		work in process			
Manufacturing Goods Work in process 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916271 1916		(b) Closing Stock		1019003	2002082
Net Inventory Adjustments (a-b) Total 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1619603 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916271 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916289 1916					
PL-5 EMPLOYEE BENEFITS EXPENSE Salary & wages & Bonus Gratuity 6949327 6755768 69808 37858 37858 Staff Welfare Exp. 415978 730115 730115 Director's Remuneration Contribution for Provident Fund Contribution for ESIC 104784 72520 72520		Work in process			1619603
PL-5 EMPLOYEE BENEFITS EXPENSE 6949327 6755768 Salary & wages & Bonus 6949327 6755768 Gratuity 69808 37858 Staff Welfare Exp. 415978 730115 Director's Remuneration 4230000 3360000 Contribution for Provident Fund 104784 72520 Contribution for ESIC 38325 18078					
Salary & wages & Bonus 6949327 6755768 Gratuity 69808 37858 Staff Welfare Exp. 415978 730115 Director's Remuneration 4230000 3360000 Contribution for Provident Fund 104784 72520 Contribution for ESIC 38325 18078		Net Inventory Adjustments (a-b)	Iotal	(296668)	912989
Salary & wages & Bonus 6949327 6755768 Gratuity 69808 37858 Staff Welfare Exp. 415978 730115 Director's Remuneration 4230000 3360000 Contribution for Provident Fund 104784 72520 Contribution for ESIC 38325 18078	PL-5	EMPLOYEE BENEFITS EXPENSE			
Staff Welfare Exp. 415978 730115 Director's Remuneration 4230000 3360000 Contribution for Provident Fund 104784 72520 Contribution for ESIC 38325 18078				6949327	6755768
Director's Remuneration 4230000 3360000 Contribution for Provident Fund 104784 72520 Contribution for ESIC 38325 18078		-			
Contribution for Provident Fund10478472520Contribution for ESIC3832518078		·		1	
Contribution for ESIC 38325 18078				1	
			Total		

ISHIT	A DRUGS AND INDUSTRIES LTD.		29 th ANNUAL RE	EPORT 2021-22
				(Amount in ₹)
Notes			As at 31-Mar-22	As at 31-Mar-21
PL-6	FINANCIAL CHARGES			
	Interest		42938	185316
	Other financial charges		202957	130988
	-	Total	245894	316304
PL-7	OTHER EXPENSES:			
Α	MANUFACTURING EXPENSE			
	Stores & Spare		461870	593137
	Power & Fuel		2272577	2446367
	Repairs to Plant & Machinery		1064627	1423210
	Process Related Exp.		69500	59300
	Laboratory Exp.		239967	342754
	Research & Development Expenses		169966	156899
	ETP Maintenance Exp.	+	1152351	1144008
_	A DAMANGED ATIVE EVENIOR	Total	5430859	6165673
В	ADMINISTRATIVE EXPENSE		60000	25005
	Books & Periodicals		62388	35095
	Repairs To Building		554096	444200
	Repairs To Others		478136	338643
	Insurance Exp.		316176	358506
	Printing & Stationery Exp. Postage & Telephones		178134 133662	188263 111923
	Office and General Exp.		1563047	1164697
	Motor Car Expenses		315040	213787
	Payment to Auditor		29000	29000
	Legal & Professional fees		1859345	1256127
	Listing, Filing & License fees		446728	426445
	Share Transfer Exp.		56883	70106
	Rent, Rates & Taxes		1995180	2165252
		Total	7987813	6802044
С	SELLING & DISTRIBUTION EXPENSE			
	Traveling & Conveyance		496947	348156
	Freight & Forwarding		949068	1653942
	Sales Commission		1558270	1450933
	Advertisement		43200	44668
		Total	3047485	3497699
	GRAND TOTAL (A+B+C)		16466158	16465416

NOTE N: SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART OF BALANCE SHEET AND STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 31.03.2022.

Significant Accounting Policies adopted by the Company in the preparation and presentation of the Accounts.

ACCOUNTING CONVENTION

The financial statements have been prepared in accordance with the Indian Accounting Standards (IndAS) notified under the Companies (Indian Accounting Standard) Rules, 2015, and stipulations as applicable under Section133 of the Companies Act, 2013, as amended from time to time, and other provisions of applicable laws.

These financial statements are prepared and presented under historical cost convention on accrual basis of accounting, except for certain assets and liabilities, which are to be measured at fair value, in accordance with IndAS.

FIXED ASSETS

Fixed assets are stated at historical cost less depreciation.

DEPRECIATION

Depreciation of Fixed Assets is calculated and provided as per Companies Act, 2013. The depreciation has been calculated considering the useful life of an asset as stipulated in Part C of Schedule II of Section 123 of the Companies Act 2013. However, in case of certain asset class, as detailed below, the useful life has been considered based on the present condition of the assets.:

- 1. Computers & Data processing units: Against the stipulated useful life of 3 years, we have considered useful life of 5 years, as even 4 years old computers are presently in use.
- 2. Office equipment: Against the stipulated useful life of 5 years, we have considered useful life of 10 years, based on the condition and our experience of the office equipment.
- 3. Mobile Phones: We have considered useful life of 5 years for mobile phones with effect from this financial year.

Apart from the above, for assets where the residual useful life is NIL as per the Part C, the carrying amount of the asset (after retaining the residual value) has been depreciated in the current year.

Depreciation on the additions is calculated pro rata from the date of additions. Depreciation is not provided on deletion of assets, as it has no effect on the results of the Company.

INVESTMENTS

Long term investments are stated at cost less provision for diminution, if any, in the value of such investments. Diminution in the value is provided for where the management is of the opinion that the diminution is of a permanent nature. Short term investments are valued at lower of cost or net realizable value.

INVENTORIES

a) Packing & fuel are valued at cost on FIFO Basis.

- b) Raw materials are valued at cost on FIFO Basis.
- c) Finished goods are valued at cost or market value whichever is lower.
- d) Work in progress is valued at cost.

MODVAT

Cenvat benefit is accounted on accrual basis on purchase so raw materials and capital goods and on actual payment basis on input services. The Cenvat benefit is appropriated against payment of excise duty on clearance of excisable goods.

SALES

Sales are accounted exclusive of Goods and Services Tax (GST) post GST implementation and inclusive of Excise Duty.

FOREIGN CURRENCYTRANSACTIONS

Foreign Currency transactions are recorded at exchange rate prevailing on the date of transaction/ realization. Current Assets / Liabilities are taken at transaction value. Diminution in the value is provided for where the management is of the opinion that the diminution is of a permanent nature. The resultant difference, if any, on realization is recognized in the profit & loss account.

CUSTOM DUTY

Custom duty is charged in the year when it is paid.

PROVISION FOR RETIREMENT BENEFITS

Gratuity: The Company's obligations towards gratuity to employees has been provided for at actuals and other retirement benefits as per policy of the company have been provided for as per IndAS-19. The same have been charged in the profit and loss of the Company.

Provident Fund: The employer and employee make statutory contribution towards the Government's Provident Fund and the same is charged in the profit and loss of the Company.

EXPENSES

Material known liabilities are provided based on available information/estimates.

TIMING REVENUE RECOGNITION

In appropriate circumstances, revenue (income) is recognized when no significant uncertainty as to measurability or collectability exists.

TAXATION

Provision for taxation is made based on the current tax rates in force.

Deferred tax charge or credit (reflecting the tax effect of timing difference between accounting income and taxable income for the period) is determined in accordance with the IndAS-12.

29th ANNUAL REPORT 2021-22

ISHITA DRUGS AND INDUSTRIES LTD.

The deferred tax charged or credited and the corresponding deferred tax liabilities or assets are recognized using the tax rate that have been enacted or subsequently established by the Balance Sheet date. Deferred tax assets are recognized and carried forward to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised.

CASH FLOW STATEMENT

Cash flows are reported using indirect method, whereby profit before tax is adjusted for the effects of transactions of a non cash nature and any deferrals or accruals of past and future cash receipts and payments. The cash flows from regular operating, investing and financing activities of the Company are segregated.

CONTINGENT LIABILITIES

All liabilities have been provided for in the accounts except liabilities of a contingent nature, which have been disclosed at their estimated value in the notes on accounts.

IMPAIRMENT OF ASSETS

Impairment loss, if any, is recognized in accordance with the accounting standard IndAS-36.

PRIOR PERIOD ITEMS

Material items of prior period non-recurring and extra ordinary items, if any, are disclosed separately.

NOTES:

- 1. Tax provision for income tax has been made as per the Income Tax Act, 1961.
- Debit and credit balances in respect of debtors, loans and advances and creditors are subject to confirmation and reconciliation.
- 3. In accordance with the IndAS-21, net profit of ₹4.54 lacs (PY Loss of ₹ 2.69 lacs) due to foreign exchange fluctuations arising on foreign currency transactions has been considered in the Profit and Loss Account.
- 4. In the year under review, the Company has provided the gratuity ₹ 69808 (P.Y.₹ 37858) towards gratuity calculated up to the date of Balance Sheet date according to the Gratuity Act on incremental basis.
- 5. The company has accounted for deferred tax assets of ₹ 119986 (P.Y. deferred tax assets of ₹ 58840) for the year under review as per IndAS-12 in the profit and loss account.
- Contingent liability to the extent not provided for ₹NIL (P.Y ₹NIL)

- 7. Previous year figures have been regrouped and reclassified wherever necessary to be in conformity with the current year figures.
- 8. Estimated amount of capital contracts remaining to be executed and not provided for net of advance paid ₹ NIL (PY₹NIL).
- 9. Managerial Remuneration paid:

	2021-22	2020-21
	Mg. Dir.	Mg. Dir.
(a) Salary₹	4230000	3360000
(b) Perks/Reimbursemen	t₹	

10. Payment to Auditors (₹)

	<u>2021-22</u>	<u>2020-21</u>
As an auditor	29000	29000
For Taxation & Other works	10000	10000
For Tax Audit	6000	6000
Out of Pocket Expense	4000	4000

- 11. The Company has not received any information from any of the suppliers of their status as Small Scale Industrial Unit. Hence, the amounts due to them outstanding as at 31st March 2022 is not ascertainable.
- 12. Related party disclosures as per the Accounting Standard AS-18 issued by the Institute of Chartered Accountants of India:
 - a. List of related parties
 - Subsidiaries: The Company does not have any subsidiary Company.
 - ii. Key Management Personnel Mr. Jagdish Agrawal Mr. Sumit Agrawal
 - iii. Relatives of Key Management Personnel Ishita Pharmaceuticals Anvi Lifesciences Pvt Ltd J & J Chemicals
- b. Transactions / balances outstanding with Related parties

Particulars	Key Management Personnel Amount in ₹	Relatives of Key Management Personnel Amount in ₹
Managerial Remuneration	7410000	
Sales of Goods / Services		62415620
Purchases of Goods /Services		43000724
Investment in equity shares/ Share Application Money		1300000
Loans/advance at year end		300000
Lease Rent		1892970

Note: Related parties are as identified by the Company and relied upon by the auditors.

29th ANNUAL REPORT 2021-22

Prev. Yr. ₹

Curr. Yr. ₹

13. Earning per Shares (EPS) as per Indian Accounting Standard AS-33

Particulars	2021-22 Amount ₹	2020-21 Amount ₹
Profit after Tax	8049668	8296227
Weighted Average no. of equity shares of ₹ 10 each Basic Diluted	2990300 2990300	2990300 2990300
EPS (₹ .) Basic Diluted	2.69 2.69	2.77 2.77

Additional information pursuant to the provisions of Companies Act, 2013.

14. Quantitative details and other information:

A Value of imports in rupees calculated on CIF basis in respect of;

Material 34789023 13245020

B Expenditure in foreign currency:

 Purchases of materials
 22335679
 23288539

 Miscellaneous Expenses
 203851
 30900

C Value of raw materials, stores and spares consumed :

, ,		₹	%	₹	%
(a)	Value of raw material consumed :				
	Imported	34676821	36	16021652	16.85
	Indigenous	61890200	64	79042262	76.41
		96567021	100.00	95063914	100.00
(b)	Value of stores and spares consumed:				
	Indigenous	461870	100.00	593137	100.00
		461870	100.00	593137	100.00

D Amount remitted in foreign currency on

account of dividend NIL NIL

E Earnings in foreign exchange (₹) 11888657 17321339

Signature to Notes A to N

Sd/- Sd/- Sd/- Sd/
For Jaymin Shah & Associates Chartered Accountants Managing Director Director

Sd/- Sd/
Mrs.Abha Agrawal
Director CFO

Ahmedabad

Dated: 30th May, 2022

BALANCE SHEET ABSTRACT AND COMPANY'S GENERAL BUSINESS PROFILE

Registration Details

Registration No. L24231GJ1992PLC017054 State Code 04

Balance Sheet Date 31-Mar-22

Capital raised during the year (Amount in thousands)

Public IssueNILRights IssueNILBonus IssueNILPrivate PlacementNIL

Position of Mobilisation and Deployment of Funds. (Amount in thousands)

Total Liabilities 112540 Total Assets 112540

Source of Funds

Paid up Capital29903Secured Loans0Reserves & Surplus56053Deferred Tax291

Current Liabilities 26292

Application of Funds

Net Fixed Assets 8846 Current Assets 100472

Investments 2715 Long term Loans & Advance 507

Performance of the Company (Amount in thousands)

Turnover 141967 Total expenditure 131537

Profit before tax 10430 Profit after tax 8050 Earning per Share Rs. 2.69 Dividend Rate (%) 0%

Generatic Names of Three Principal Products/services of Company.

(as per monetary terms)

Item Code No. (ITC Code)29419060Product DescriptionNORFLOXACINItem Code No. (ITC Code)29362920Product DescriptionNICOTINIC ACID

Item Code No. (ITC Code) 29359015

Product Description SULFONAMIDES

Note : Classification of products/services under ITC code being of a technical nature is not verified by the Auditors. As per our attached report of even date.

Sd/- Sd/- Sd/- Sd/- Sd/- Govind Gupta
Chartered Accountants Managing Director Director

Sd/- Sd/Ahmedabad Mrs.Abha Agrawal Sumit Agrawal
Dated: 30th May, 2022 Director CFO

Registered Office : Survey No. 179/1 , Vasna Iyava, Sanand.

Form No. MGT-11
Proxy Form

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

	e of the obers			
Regi	stered address :			
_	ail ld:			
Folio	No. / Client Id:			
DP I	D:			
I/We, I	being the holder(s) of equity shares of ISHITA DRUGS AND INDUSTRIES LIN	IITED, he	reby appoint	
1. Nar	ne :E-mail Id :			
Addre	SS:			
	Signature :	or fail	ng him/her	
2. Nar	ne :E-mail Id :			
Addre	ss:			
	Signature:			
	our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 29 th Annual General Moneld on Friday, 30 th September, 2022 and at any adjournment thereof	eeting of t	ne Company,	
Sr.	Particulars	For	Against	
No.				
<u> </u>	ORDINARY BUSINESS			
1.	To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2022, together with the Reports of Board of Directors and Auditors thereon.			
2.	Re-appointment of Mrs. Abha Agrawal (DIN 01589479), as Director, who retires by rotation.			
3.	To consider the Re-appointment of M/s Jaymin Shah & Associates, Chartered Accountants (FRN No. 129406W) as the Statutory Auditor of the Company for a period of one year.			
	SPECIAL BUSINESS			
4.	To increase in the Authorised Share Capital of the Company, and the consequential Alteration in Clause-V of Memorandum of Association of the Company.			
5.	To Adopt the revised Articles of Association of the Company to align it with the regulations of the Companies Act, 2013. (Special Resolution)			
		Г	Affix	
Sign	ed this day of 2022		100 Paise	
Sign	ature of Share holder Signature of Proxy holder(s)		Revenue Stamp	
Note	: This form duly completed and signed must be deposited at the registered Office of the Company not less than 48	hours befor	e the Meeting.	
94	· · · · · · · · · · · · · · · · · · ·			
	ISHITA DRUGS AND INDUSTRIES LTD			
	Registered Office: Survey No. 179/1, Vasna Iyava, Sanand.			
	Attendance Slip			
	(To be handed over at the entrance of the meeting hall) 29th Annual General Meeting - 30th September 2022			
DP ID) :			
	NT ID :			
	FOLIO No. : No. of Shares held			
	by record my presence at the TWENTY NINTH ANNUAL GENERAL MEETING of the Company held at "I Ir. Rexroth Bosch, Village Iyava, Taluka Sanand, Sanand Viramgam Highway, Gujarat 382170 at 11.30 A.N		Hotel Krsna	
	ame of Proxy (in BLOCK LETTERS)			

NARODA 43|SI NAROLGAM VATVA Akmedabad sovergre Route Map of Venue of AGM [142] GOTA Santej सातेल Shela Pipan Muq 138 Bol B Khoraj ખોરજ

By Courier / Registered / Speed Post

Ъ,

If undelivered, please return to:

Ishita Drugs & Industries Limited

Regd. Office: Survey No. 179/1, Village: Vasna-Iyava,
Taluka: Sanand, District: Ahmedabad - 382 170.